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Introduction 
Ibuprofen is a non-steroidal anti-inflammatory agent with analgesic and antipyretic activity. 
It is indicated for rheumatoid arthritis, osteoarthritis, mild-to-moderate pain, primary 
dysmenorrhea, and reduction of fever. Ibuprofen is available in the form of tablets, capsules, 
injections, suspensions, suppositories, gels, creams and mousses. 
Objectives 
The objectives of this study were: 
1. To develop and validate a suitable high performance liquid chromatographic method 
with the necessary sensitivity to accurately and precisely quantitate ibuprofen in aqueous 
solution. 
2. To utilise an appropriate diffusion technique for the measurement of the amount of 
ibuprofen released from a topical formulation during in vitro testing. 
3. To verify the usefulness, or otherwise, of shed snake skin as a biological diffusion 
membrane. 
4. To assess the permeation of ibuprofen using shed snake skin as the biological animal 
membrane. 
5. To conduct a comparative diffusion study on proprietary ibuprofen-containing topical 
preparations from three countries. 
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ABSTRACT 
Ibuprofen is a non-steroidal anti-inflammatory drug with three major types of effect: anti-
inflammatory, analgesic and antipyretic. Ibuprofen may be administered in a number of 
different forms via the oral as well as the topical route. Published evidence suggests that 
topical, unlike oral, non-steroidal anti-inflammatory drugs are associated with few systemic 
side effects as plasma concentrations are low compared to oral therapy. 
In some countries it is particularly difficult to obtain human skin for in vitro experimentation 
and it is therefore important to have alternate biological or synthetic membranes which 
mimic human skin for diffusion experiments. Synthetic membranes serve as predictive 
models for topical drug release and in South Africa, shed snake skin is easily obtainable 
from the many snake parks present in the country. 
The FDA guidelines were considered when choosing the apparatus to be used in the 
comparative diffusion study on proprietary ibuprofen-containing topical preparations from 
three countries and the verification of the usefulness, or otherwise, of shed snake skin as a 
biological membrane for the assessment of the permeation of ibuprofen. Two diffusion 
techniques were considered appropriate for the measurement of the amount of ibuprofen 
released from a topical formulation during in vitro testing. One was the Franz diffusion cell, 
as modified by Keshary and Chien (88,169) and the other was the European Pharmacopoeia 
diffusion cell (187). 
High performance liquid chromatography was used as the analytical technique for the 
analysis of ibuprofen in aqueous solution using ultraviolet detection at 222 nm. The 
validated method was applied to the determination of the diffusion of ibuprofen from topical 
ibuprofen-containing formulations (gels, creams and mousse) through synthetic silicone 
membrane and shed snake skin biological membrane from four different species. 
In a study of fifteen topical ibuprofen-containing formulations (gels, creams and mousse) 
from three countries (South Africa, United Kingdom and France) it was found that there was 
a trend of products from two countries consistently exhibiting superior diffusion 
characteristics as well as products from the same two countries consistently exhibiting the 
lowest diffusion of ibuprofen. Interpretation of the results of these studies demonstrated the 
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importance of employing a combination of statistical analyses and peak integration values 
when drawing conclusions regarding comparative diffusion characteristics. 
Shed snake skin has been described as a 'model' membrane, i.e. a membrane which shows 
similar permeability to human stratum corneum. The results reported here show clearly that, 
for ibuprofen, the four species of snake produce shed skin with completely different 
diffusion characteristics when all other conditions are identical. It may well be that there is 
one particular species of snake which produces shed skin of identical permeability to human 
stratum corneum, but to describe shed snake skin in general as a model membrane seems 
incorrect. It is therefore important that if shed snake skin is used as a membrane, the species, 
skin site and orientation should be reported. 
The European Pharmacopoeia diffusion apparatus was judged to be the better of the two 
diffusion techniques assessed for the measurement of the amount of ibuprofen released from 
a topical formulation during in vitro testing using silicone membranes and for the 
measurement of the amount of ibuprofen diffusing across the ventral outside orientation of 
shed skin during in vitro testing, whereas the Franz diffusion apparatus was judged to be 
better for the measurement of the amount of ibuprofen diffusing across the dorsal outside 
orientation of shed skin during in vitro testing. However, the choice of this diffusion 
apparatus must be weighed against the relatively poor reproducibility as compared with the 
European Pharmacopoeia diffusion apparatus. 
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CHAPTER ONE 
IBUPROFEN MONOGRAPH 
1.1 PHYSICOCHEMICAL PROPERTIES OF mUPROFEN 
1.1.1 Description 
Ibuprofen is (RS)-2-( 4-isobutylphenyl)-propionic acid. It contains not less than 98.S% and 
not more than 101.0% of C13H1S0 2, calculated with reference to the dried substance (1-4). 
Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) used in painful and 
inflammatory conditions. It is a white powder or colourless crystalline solid with a slight 
odour and taste (1,2,4). Ibuprofen is non-hygroscopic and is physically and chemically 
stable in the dry state. It is prepared chemically and is marketed as the racemic mixture of 
its two enantiomers (4). 
OH 
Figure 1.1 Structure of ibuprofen (molecular mass 206.3) 
1.1.2 Melting Range 
Ibuprofen melts in the range of 7SoC to 78°C (2). 
1.1.3 Solubility 
Ibuprofen is practically insoluble in water but is soluble 1 in 1.5 of ethanol, 1 in 2 of ether, 
1 in 1 of chloroform, and 1 in I.S of acetone. Ibuprofen is readily soluble in most organic 
solvents and is soluble in aqueous solutions of alkali hydroxides and carbonates. It is 
freely soluble in dichloromethane (2,4,S). 
Solubility increases at pH values higher than the pKa. The approximate solubilities at pH 
4, pH 6, and pH 7 are 1 in 35 000, 1 in 1 900, and 1 in 410 respectively (2). 
1.1.4 Dissociation Constant 
The dissociation constant (pKa) of ibuprofen is reported as 4.41 (35) and in a 60% ethanol 
solution as 5.2 (2). 
1.1.5 Partition Coefficient and Permeability Coefficient 
The octanol water partition coefficient (log P) is reported as 3.51. It has been shown that 
for maximum percutaneous absorption to take place log P should be in the range of 2-3. 
At low log P, the permeability coefficient is low but the aqueous solubility is high, while at 
high log P, the permeability coefficient is high but the aqueous solubility is low. The 
permeability coefficient is 4.36 x 10-2 crnlh for the un-ionised drug in an aqueous 
formulation (35,36). 
1.1.6 Maximum Flux 
The maximum flux through the skin is obtained by multiplying the permeability 
coefficient, for the un-ionised drug in aqueous formulation, and aqueous solubility. The 
maximum flux (]max) is reported as 0.61 Jlg/cm2/h (35). 
1.1.7 Dissolution 
The United States Pharmacopoeia (USP) specifies that for Ibuprofen Tablets USP, not less 
than 70% of the labelled amount of C13H180 2 dissolves in 30 minutes. The dissolution 
medium is 900ml of phosphate buffer at a pH of 7.2, using apparatus 1 at 150 rpm (2). 
1.1.8 Molecular Structure 
Ibuprofen has a chiral centre in the propionic acid moiety and can exist in two 
enantiomeric forms. In vivo and in vitro studies indicate that only the S(+)-enantiomer of 
ibuprofen has clinical activity. On administration of the racemic mixture, the 
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pharmacologically inactive R( -)-enantiomer is converted to the active S( + )-enantiomer. A 
stereoselective assay is therefore necessary for pharmacokinetic studies (2,6). 
~CH3 a~nthetas~H3 ~ ~CH3 
\ '---J 'COOH \ '---J 'co SCoA \ '---J 'COOH 
R( -)-Ibuprofen R( -)- Ibuprofen CoA R( -)-Ibuprofen 
II racemase 
: ~ : ~fH3 acyl COAsYn~tetase fH3 \. j . COOH \. j . COOH 
S(+)-Ibuprofen S(+)- Ibuprofen CoA 
Figure 1.2 Stereospecific inversion of R( -) to S( + )-ibuprofen (37) 
1.1.9 Ultraviolet Absorption Spectrum 
The ultraviolet absorption spectrum of ibuprofen in O.OIM solution of sodium carbonate is 
depicted in Figure 1.3. The spectrum was obtained using a GBe UVNis 916 
Spectrophotometer. 
This spectrum is similar to that found in the literature (7). 
Figure 1.3 
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1.2 CLINICAL PHARMACOLOGY OF IBUPROFEN 
1.2.1 Preparations 
Ibuprofen may be administered in a number of different forms (5) via the oral as well as 
the topical route. Published evidence suggests that topical, unlike oral, NSAIDs are 
associated with few systemic side effects as plasma concentrations are low compared to 
oral therapy. 
ROUTE FORM STRENGTH 
Oral Liquid-filled capsules 200mg 
Suspensions 40mglml 
100mg/5ml 
Tablets 200mg 
400mg 
600mg 
800mg 
Chewable tablets 50mg 
100mg 
Film-coated tablets 100mg 
200mg 
300mg 
400mg 
600mg 
800mg 
Topical Gel 5%mlm 
Cream 5%mlm 
Mousse 5%mlm 
Table 1.1 Ibuprofen preparations 
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1.2.2 Mode of Action 
Ibuprofen is a NSAID with three major types of effect: 
• Anti-inflammatory effect 
• Analgesic effect 
• Antipyretic effect 
Ibuprofen, as a NSAID, has the ability to alter the production of certain biochemical 
mediators, including prostaglandins and thromboxanes. Prostaglandins and thromboxanes 
are produced by the action of cyclo-oxygenase (COX) on arachidonic acid and are 
mediators of the inflammatory process (9,10). The primary action of ibuprofen is therefore 
the inhibition of arachidonate cyclo-oxygenase and thus inhibition of the production of 
prostaglandins and thromboxanes (11-14). 
There are two types of cyclo-oxygenase, namely COX-1 and COX-2. COX-1 is a 
constitutive enzyme expressed in most tissues, including blood platelets, and is involved in 
cell-cell signalling, while COX-2 is induced in inflammatory cells when they are activated 
and is believed to be the enzyme that produces the prostanoid mediators of inflammation 
(11-14). 
Inhibition of prostaglandin biosynthesis prevents their hyper-analgesic effect upon sensory 
nerves while inhibition of vasodilator prostanoid formation (prostaglandin E2) diminishes 
the vascularity and transudation of fluid which are two of the principal manifestations of 
inflammation. 
Prostaglandins of the E and F series are potent uterotropic agents and their biosynthesis is 
normally increased in the hours before parturition, therefore ibuprofen, by inhibiting their 
formation, may slow the onset of labour. Inhibition of the formation of thromboxane A2 by 
the platelets results in the platelets being less likely to aggregate in response to a 
thrombogenic stimulus (4). 
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1.2.3 Indications 
Ibuprofen is used for its anti-inflammatory, analgesic and antipyretic effects in the 
management of conditions such as dysmenorrhoea, migraine, postoperative pain, 
ankylosing spondylitis, pericarditis, cystic fibrosis, osteoarthritis and rheumatoid arthritis 
including juvenile rheumatoid arthritis, and in other musculoskeletal and joint disorders 
such as sprains and strains (3-5,9,15). 
In patients with primary dysmenorrhea, ibuprofen has reduced resting and active intra-
uterine pressure and the frequency of uterine contractions, probably as a result of inhibition 
of prostaglandin synthesis (6). 
In non-articular rheumatism which includes bursitis, fibrositis, lumbago, tenosynovitis, 
neck pain and myalgia of all types, ibuprofen is a suitable drug for management. Sports 
injuries and acute musculoskeletal trauma are other indications for ibuprofen (3,4,15). 
Ibuprofen is one of the best tolerated NSAIDs for symptomatic relief of osteoarthritis and 
its effectiveness in achieving and maintaining control of pain coupled with its good 
tolerance, makes it a first line therapy for all forms of osteoarthritis (3,4,15). 
Ibuprofen exhibits anti-inflammatory activity by reducing heat, tenderness, and swelling of 
joints in patients with rheumatoid arthritis resulting in an improvement in exercise 
tolerance, grip strength, and overall function. Oral ibuprofen is therefore recommended as 
first-line therapy in the majority of patients as it is effective, inexpensive and has the 
lowest reported incidence of side-effects, while topical ibuprofen is promoted on the basis 
that it diffuses rapidly and directly into joints resulting in high local and low plasma 
concentrations of the drug, thus giving a lower risk of systemic side effects than oral 
NSAIDs (9). Ibuprofen has been reported to be effective in the management of juvenile 
rheumatoid arthritis, particularly in patients who are unable to tolerate aspirin (3-5,9). 
1.2.4 Adverse Reactions 
The most frequent adverse effects occurring with ibuprofen are gastro-intestinal 
disturbances. Prostaglandins, particularly prostaglandin I2 and prostaglandin E2, are 
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synthesised by the gastric mucosa and seem to promote the secretion of cytoprotective 
mucus, therefore ibuprofen, by inhibiting the synthesis of these prostaglandins, may lead to 
gastro-intestinal disturbances (4,18). Reactions range from abdominal discomfort, nausea, 
vomiting, and abdominal pain to serious gastro-intestinal bleeding or activation of peptic 
ulcers (3-5,9). 
Central nervous system related side effects include headache, dizziness, nervousness, 
tinnitus, depression, drowsiness and insomnia. Hypersensitivity reactions that occasionally 
occur include fever and rashes while hepatotoxicity and aseptic meningitis occur only 
rarely (3-5,19). 
Ibuprofen has little effect on renal function in normal individuals but can precipitate renal 
failure in patients who depend upon the vasodilatory action of prostaglandin E2 or I2 to 
maintain renal blood flow. This occurs in hypertension, diabetes, cirrhosis of the liver and 
a number of other conditions (4). In cases such as these, ibuprofen and other non-steroidal 
anti-inflammatory drugs may cause cystitis and haematuria as well as acute renal failure, 
interstitial nephritis, and nephrotic syndrome (3,4,20-23). Ibuprofen may occasionally 
promote salt and water retention by interfering with the prostaglandin-induced inhibition of 
both chloride reabsorption and the action of anti-diuretic hormone (4). 
Dermatologic effects which have occasionally occurred during ibuprofen therapy include 
urticarial, vesiculobullous, and erythematous macular rashes, erythema multiforme, 
exfoliative dermatitis, toxic epidermal necrolysis and photosensitivity reactions. Stevens-
Johnson syndrome, flushes, alopecia, rectal itching and acne have also been reported (5). 
Adverse haematologic effects include neutropenia, agranulocytosis, aplastic anaemia, 
haemolytic anaemia (with or without positive direct antiglobulin test results), and 
thrombocytopenia (with or without purpura). Although a causal relationship has not been 
established, bleeding episodes have been reported during therapy with the drug. Ibuprofen 
can inhibit platelet aggregation and may prolong bleeding time (5,16). 
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1.2.5 Contraindications 
MOST SIGNIFICANT 
• Acetylsalicylic acid allergy 
SIGNIFICANT 
• Bleeding disorder 
• Duodenal ulcer 
• Gastric ulcer 
• Peptic ulcer 
• Stomatitis 
• Systemic lupus 
• Erythematosus 
• Ulcerative colitis 
• Upper gastro-intestinal disease 
POSSIBL Y SIGNIFICANT 
• Bronchial asthma 
• Cardiac disease 
• Congestive heart failure 
• Hepatic function impairment 
• Hypertension 
Table 1.2 Drug disease contraindications 
The risk of potentially serious adverse gastro-intestinal effects should be considered in 
patients receiving ibuprofen, particularly in patients receiving chronic therapy with the 
drug (4,9,16,24). Ibuprofen should be used with caution in patients with peptic ulcer 
disease, gastro-intestinal perforation or bleeding, bleeding abnormalities (especially in 
patients who may be adversely affected by prolongation of bleeding time), impaired renal 
function, hypertension or compromised cardiac function (4,5). 
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Renal prostaglandins may playa supportive role in maintaining renal perfusion in patients 
with pre-renal conditions, therefore administration of ibuprofen to such patients may cause 
a dose-dependent reduction in prostaglandin formation and thereby precipitate overt renal 
decompensation. Patients at greatest risk of this reaction include those with impaired renal 
function, heart failure or hepatic dysfunction; those with extracellular fluid depletion, those 
receiving a nephrotoxic drug concomitantly, those with elevated levels of angiotensin IT or 
catecholamines and geriatric patients (5). 
Ibuprofen is contraindicated in patients with known hypersensitivity to the drug and in 
patients in whom bronchospasm, angioedema or nasal polyps are precipitated by aspirin or 
other NSAIDs. Ibuprofen is contraindicated in patients in whom urticaria, angioedema, 
bronchospasm, severe rhinitis or shock is precipitated by aspirin or other NSAIDs since 
anaphylactoid reactions have occurred in such patients (4,5,9). 
The safe use of ibuprofen during pregnancy has not been established. Ibuprofen inhibits 
prostaglandin synthesis and release which may cause dystocia, interfere with labour, delay 
parturition and may also have adverse effects on the foetal cardiovascular system. Use of 
ibuprofen is not recommended during pregnancy (especially during the last trimester) or 
during labour and delivery (5). 
1.2.6 Drug Interactions 
In several short-term, controlled studies, ibuprofen did not have a substantial effect on the 
prothrombin time of patients receiving oral anticoagulants. However, because ibuprofen 
may cause gastro-intestinal bleeding, inhibit platelet aggregation and prolong bleeding 
time, the drug should be used with caution and the patient carefully observed if the drug is 
used concomitantly with any anticoagulant or thrombolytic agent (4,5). 
Aspirin and ibuprofen should not be given together because of the displacement of 
ibuprofen from serum binding sites and thus a reduction in plasma ibuprofen levels. In 
addition, concomitant administration of ibuprofen and salicylates, phenylbutazone, 
indomethacin or other NSAIDs could potentiate the adverse gastro-intestinal effects of 
these drugs and therefore ibuprofen probably should not be administered with these agents 
(4,5). 
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Ibuprofen has been reported to increase plasma or serum lithium concentrations by 12 -
67% and to reduce renal lithium clearance. The mechanism involved in the reduction of 
lithium clearance by NSAIDs (including ibuprofen) is not known but has been attributed to 
inhibition of prostaglandin synthesis, which may interfere with the renal elimination of 
lithium. Some clinicians recommend that patients receiving lithium should not receive 
ibuprofen. However, if ibuprofen and lithium are used concurrently, the patient should be 
closely observed for signs of lithium toxicity, and plasma or serum lithium concentrations 
should be monitored carefully during the initial stages of combined therapy or subsequent 
dosage adjustment (25-28). 
1.2.7 Toxicity 
Adverse effects associated with an overdose of ibuprofen usually depend on the amount of 
drug ingested and time elapsed, however, because individual response may vary, each 
occurrence should be evaluated individually. Occasionally overdosage of ibuprofen has 
been associated with severe toxicity, including death (6,29). 
The most frequent manifestations of an ibuprofen overdose are abdominal pain, nausea, 
vomiting, lethargy, and drowsiness. In addition, other adverse effects, including headache, 
tinnitus, central nervous system depression, seizures, hypotension, bradycardia, 
tachycardia and atrial fibrillation may occur (30-34). Metabolic acidosis, coma, acute 
renal failure, hyperkalemia, apnoea (mainly in young children), respiratory depression and 
respiratory failure have rarely been reported (6,29). There appears to be little correlation 
between severity of manifestations associated with ibuprofen overdosage and plasma 
ibuprofen concentrations (30-34). 
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1.3 PHARMACOKINETICS OF TOPICAL IBUPROFEN 
The pharmacokinetics of a topically applied ibuprofen cream have been investigated and 
compared to the results obtained after oral administration of ibuprofen (38). In this study, 
a maximum serum concentration (Cmax) of 0.64 Jlg/ml of ibuprofen was found after two 
hours for a topical application of 300 mg ibuprofen. The maximum serum concentration is 
understandably significantly lower than that found after oral administration of 400 mg 
(Cmax = 38.9 Jlg/ml at 2 hours). Assuming the absorption after oral administration was 
100%, and adjusting for the differing dosage sizes, an absorption rate of 5% was calculated 
for topical administration. 
Investigations into the pharmacokinetics of a topically applied ibuprofen gel have also 
been conducted. In one study a percutaneous absorption rate of 3% was found, with 
reference to an equivalent ibuprofen dose (39). This study yielded a maximum serum 
concentration of 0.2 Jlg/ml after 11 hours for a topical application of 400 mg of ibuprofen. 
A second study of a topically applied ibuprofen gel (200 mg ibuprofen) found the 
maximum serum concentration to be lAO ± 0040 Jlg/ml which occurred at 4.83 ± 1.83 
hours (40). In this study the use of an 8 hour occlusion period led to higher plasma 
profiles. A third study of a topically applied ibuprofen gel (500 mg ibuprofen) found the 
maximum serum concentration to be 7.1 ± 404 Jlg/ml which occurred at 2.4 ± 0.8 hours 
(41). The relative bioavailability of the ibuprofen gel formulation was reported as 22 ± 
12%, determined as the dose corrected value with the oral dose set at 100%. 
Several factors contribute to the differences between the results reviewed in the literature 
for topical ibuprofen. In general, the maximum serum concentration is dependent on the 
application site, the application surface, the duration of occlusion, the dosage and type of 
formulation. In three of the studies reviewed the application site and surface were identical 
[20 x 20 cm area on the upper back (38,39,41)]. In the fourth study, the application site 
was 20 x 18 cm on the upper back (40). The dose varies from 200 to 500 mg ibuprofen, 
which may also account for the differences in the results. 
Two of the cited literature studies were performed without occlusion (38,39). Under non-
occluded conditions, the rate of trans epithelial water loss is about 6 g/m2/h (45). The use 
of occlusion prevents transepithelial water loss and thus causes swelling of the stratum 
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corneum. Swelling facilitates the penetration of ibuprofen through the stratum corneum 
into the epidermis, resulting in higher concentrations in the epidermis and eventually in the 
plasma. 
The much higher maximum serum concentration observed in the study conducted by 
Kleinbloesem (41) can be related to the type of formulation. The product contains, among 
other ingredients, isopropanol and propylene glycol. Both of these substances are 
classified as humectants and are thus capable of bringing about hydration and 
hydrophilisation of the stratum corneum, facilitating the absorption of ibuprofen. 
Propylene glycol is also classified as a penetration enhancer, which causes increased 
penetration of ibuprofen through the stratum corneum. 
Promotion of penetration is also brought about by the pH 5.0 of the gel used in the study 
conducted by Kleinbloesem (41). The pKa of ibuprofen is 4.41 (35), thus at pH 5.0, about 
40% of the ibuprofen is present in its neutral, undissociated form. This neutral form of 
ibuprofen is better able to pass through the lipophilic stratum corneum into the epidermis 
(45), where the pH of 7.4 causes a shift to about 99.9% dissociated ibuprofen. In this 
dissociated form, ibuprofen is better able to travel through the hydrophilic epidermis and 
reach the target tissues. 
Concentrations of ibuprofen in the plasma are therapeutic at level s greater than 10 J.lg/ml 
(42). After topical administration, ibuprofen levels in the plasma reach detectable levels 
surprisingly quickly (within the first half hour), however maximum serum concentration 
falls short of reaching therapeutic plasma levels (41). This is a good indication that the 
topical administration of ibuprofen does not lead to systemic adverse effects, as therapeutic 
concentrations in the circulatory system are not achieved. In contrast, it is known from the 
literature that therapeutic concentrations are achieved in the target tissues after topical 
application of ibuprofen (39,43,44). 
The principle products of metabolism, as seen in figure 1.4, are formed by 2-hydroxylation 
to 2-[4-(2-hydroxy-2-methylpropyl) phenyl]-propionic acid (-9% of the dose in urine) 
followed by conjugation (-17%) and oxidation to the 2-carboxy product, 
2-[4-( carboxypropyl)- phenyl]propionic acid (-16%) followed by conjugation (19%). 
None of the metabolites are pharmacologically active (4,37). 
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Figure 1.4 Metabolism of ibuprofen 
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CHAPTER TWO 
THEORY OF TRANSMEMBRANE DIFFUSION 
2.1 TRANSMEMBRANE DIFFUSION 
2.1.1 Introduction 
The skin is the primary area of body contact with the environment. Introduction of 
chemicals into the body via the skin occurs both through passive contact with the 
environment and through direct application of chemicals on the body for purposes of 
medical therapy and as cosmetics. Delivery systems may be placed against the skin to 
deliver drugs to the local tissues immediately beneath the application site~ deep regions in 
the vicinity of, but still somewhat remote from, the application site; and the systemic 
circulation, the latter to mediate pharmacological changes somewhere totally removed 
from the application site (144). 
Free diffusion or passive transport of substances through liquids, solids, and membranes is 
a process of considerable importance in the pharmaceutical sciences. 
2.1.2 Kinetics of the Diffusion Process 
The transmembrane diffusion process is passive in nature, requiring a concentration 
differential as the driving force and each molecule requires kinetic energy to effect a net 
movement down this gradient. The permeation of a molecule through a membrane, either 
biological or synthetic, in vivo or in vitro, would normally occur as follows (152): 
1. The molecule must diffuse through the vehicle in which it is contained to the 
membrane interface and must partition from the vehicle into the upper lamina of the 
medium. 
2. The molecule must diffuse within the membrane, equilibrating laterally and must 
emerge, eventually under steady state conditions, from the distal surface of the 
medium. Adsorptive interaction may be extensive in this layer, forming a reservoir of 
the molecule. 
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3. The molecule then partitions either into the neighbouring membrane strata or into the 
receptor fluid under the influence of the concentration gradient, and adsorption may 
occur once again. Diffusion through anyone of the layers or any of the partitioning 
events may control the overall rate of permeation. 
The experimental handling of animal membrane data resembles that for diffusion through 
homogenous synthetic media. The steady state diffusion through a homogenous medium 
may be described in terms of Fick's first law (46) which states that the rate of transfer of 
diffusant through unit area of membrane (the flux) is proportional to the concentration 
gradient measured normal to the section: 
J = -DdC/dx Equation 1 
Where J is the flux, D is the diffusion coefficient of the diffusant in the membrane, C is the 
concentration of the diffusing substance (usually taken as the concentration of the diffusant 
in the vehicle in contact with the donor surface of the membrane) and x is the distance of 
movement perpendicular to the surface of the barrier. The negative sign signifies that 
diffusion occurs in a direction opposite to that of increasing concentration, thus flux is 
always a positive quantity (152). 
Fick's first law is only applicable to diffusion in an isotropic medium and where the 
diffusant concentration at the distal surface of the membrane is zero. While synthetic 
media may comply with the isotropic constraint of the equation, the heterogeneous 
environment of snake skin may cause significant deviations from Fickian behaviour. In the 
case of diffusion through anisotropic membranes, such as snake skin, an equation for mass 
transport that emphasises the change in concentration with time at a definite location rather 
than the mass diffusing across a unit area of barrier in unit time is more applicable. For 
most experimental situations effective diffusion occurs only in one direction through the 
membrane, that of the concentration gradient (152). Fick's second law (46) states that the 
change in concentration with time in a particular region is proportional to the change in the 
concentration gradient at that point in the system: 
Equation 2 
where t is the time, and x is the diffusion distance in the direction of the concentration 
gradient. 
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In the in vitro diffusion systems used, the Franz and European diffusion cells, a membrane 
separates two chambers, one containing a constant donor concentration, and the other 
containing sink receptor conditions. Initially the concentration gradient across the 
membrane will not be linear as the diffusant equilibrates within the medium, however after 
sufficient permeation time has elapsed steady state will be achieved and the effective 
diffusant concentration at all points in the membrane will remain constant (152). For an 
infinite dose of drug applied to the donor surface of a membrane in an in vitro diffusion 
cell under sink conditions, (the permeation situation that has prevailed in this experimental 
work) Fick's second law has been expanded to the following expression as time 
approaches infinity (46): 
M = DCr/h (t- h216D) Equation 3 
where M is the cumulative mass of diffusant that has passed through unit area of 
membrane, Co is the concentration of diffusant in the membrane lamina juxtaposed to the 
donor vehicle, and h is the thickness of the membrane. This equation is applicable to the 
typical cumulative mass versus time diffusion plots that have an initial non-linear lag time 
followed by a linear steady state plot. 
By differentiating Equation 3 with respect to time an expression is obtained for the steady 
state flux (dMldt) which is the gradient of the straight line (46): 
DMldt = DCr/h Equation 4 
Normally the concentration of the diffusant in the membrane lamina at the donor surface is 
not known, however the concentration of the diffusant in the donor vehicle in contact with 
the membrane can be measured: 
DMldt = DCK/h Equation 5 
where K is the partition coefficient of the diffusant between the vehicle and the membrane. 
The product of the partition coefficient and the donor vehicle concentration will yield the 
diffusant concentration in the membrane lamina. The main variables influencing the rate 
of diffusion are thus the partition coefficient and the effective diffusion coefficient, the 
donor concentration and the membrane thickness (152). 
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The dimensions of these variables may be unknown and the equation is simplified to (46): 
dMldt = PC Equation 6 
where P is the composite permeability coefficient. The permeability coefficient is often 
quoted where the diffusion and partition coefficients cannot individually be calculated. 
The diffusion coefficient of the solute in the membrane may be estimated if the lag time 
(L) is obtained from the diffusion profile by extrapolating the linear steady state portion of 
the plot to the abscissa where M = O. If the membrane thickness is known, the diffusion 
coefficient is then given by (46): 
Equation 7 
Knowing the concentration of the diffusant in the donor vehicle, the partition coefficient 
may be estimated from the mass of the diffusant that has passed through a unit area of 
membrane. Using Equation 6, the partition coefficient may then be calculated using: 
P = KDIh Equation 8 
Therefore, all the parameters of the steady state diffusion equation may be estimated from 
the measured permeation data, if the medium thickness and donor concentration are 
known. 
In certain instances the partitioning characteristics of the drug between the vehicle and 
membrane may be highly favourable, generating high drug concentrations within the 
medium. Alternatively, the barrier potential of the membrane may be minimal or violated 
by disease, chemical or, as is the case with shedding of the snake skin, physical trauma. In 
these cases the rate of drug diffusion through the medium will be high and the 
replenishment of the partitioned diffusant at the membrane interface from the bulk vehicle 
may become the rate controlling step in the diffusion process, rather than the sensitivity of 
the membrane itself (152). Higuchi (47) proposed the mathematical relationships that are 
applicable to this situation in which the membrane is regarded as having negligible 
resistivity and sink clearance conditions are maintained throughout the diffusion time. 
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The rate of permeation would then be governed by the rate of diffusion through the vehicle 
and is expressed by the simplified equation: 
2 112 M = Co (Dvt/:r) Equation 9 
Where Dv is the diffusion coefficient of the drug in the vehicle and C represents the initial 
concentration of diffusant in the vehicle. It is apparent from this equation that the mass of 
drug permeating to the sink is proportional to the square root of the contact time between 
vehicle and membrane. Permeation of this nature has a characteristic curved profile, 
exhibiting relatively high flux at early contact times which decreases as the diffusant front 
regresses into the bulk vehicle, away from the membrane. The path is progressively more 
tortuous, and it takes longer for drug molecules to diffuse from the region of high 
concentration in the vehicle to replenish the drug molecules at the membrane interface that 
have partitioned into the membrane, therefore the flux rate decreases with time (152). 
Equations 1-9 describe the process of diffusion through an isotropic medium and these 
mathematical functions have been applied to the analysis of the data from this 
experimental study. Certain assumptions are made in their application: that sink diffusion 
conditions are maintained throughout the experiment, that extensive adsorption of the 
diffusant does not occur, and that the barrier medium is homogeneous. 
2.1.3 Modification of the Diffusion Process 
Many physicochemical factors may influence the rate of drug diffusion through a 
membrane. Although several of these factors may be controlled in laboratory diffusion 
experiments, some influences may be unavoidable and may thus affect the results obtained. 
2.1.3.1 Hydration 
An important factor which influences drug partitioning from a topical vehicle into a 
membrane, especially biological tissues, is the degree of hydration. Maintaining adequate 
membrane hydration is essential to the dissolution of the drug into, and subsequent 
diffusion through, the membrane. 
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During the diffusion experiments performed in this study, the receptor fluid was in 
continuous contact with the membrane resulting in complete hydration of the membrane. 
Further hydration was provided through the application of external occlusion which 
prevented the evaporation of water and volatile constituents from the formulation. 
Moreover, the composition of the vehicles in the occluded mode remained relatively 
constant throughout the delivery period. 
2.1.3.2 Diffusant Concentration 
The rate of diffusion is directly proportional to the concentration of drug in solution at the 
donor surface of the membrane. The greatest thermodynamic potential of an experimental 
system would be generated by a saturated solution of the diffusant in the vehicle (128). 
The viscosity of the formulation may hinder intra-vehicle drug diffusion and result in a 
steadily decreasing concentration at the membrane interface. In general, any 
physicochemical factor that may change the concentration of the drug at the membrane 
surface will alter the permeation behaviour. 
2.1.3.3 Skin Damage 
Any pathological or physical condition that alters the character of shed snake skin will 
probably alter its resistance to diffusion. Although in vitro permeation studies would 
normally use undamaged shed snake skin, there is a possibility that these membranes may 
be damaged by preparative techniques or by experimental methodology. This problem is 
not as critical when synthetic media are used as these are relatively resistant to physical 
damage. 
2.1.3.4 Partition Coefficient 
The influence of the vehicle composition on the partition coefficient is important in that 
any change in the partition coefficient will change the drug concentration established in the 
superficial lamina of the membrane. The magnitude of the partition coefficient will be 
influenced by any factors that affect the potential of the molecule to escape from the donor 
vehicle, including the degree of ionisation, complexation and adsorption. 
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The solubility of the drug in the membrane would influence its affinity for that medium. 
The drug structure-activity relationship suggests that the more lipophilic molecules would 
have greater affinity for the skin and would partition to a greater extent than polar moieties, 
however some bipolar character is essential. 
Surfactant molecules in the donor vehicle may enhance partitioning by reducing the 
surface tension between the vehicle and the membrane surface, but may also influence the 
barrier potential of the membrane (48). 
2.1.3.5 Vehicle/Dosage Form 
Many researchers have evaluated a large number of vehicles and various dosage forms for 
their effects on drug permeation through the skin (129-141). These evaluations were 
conducted in relation to both transdermal and dermatological drug delivery and based on 
both in vitro and in vivo methods. From the published literature, it is not always clear 
whether the vehicle concentration was optimal (128). This is especially true for 
extemporaneous dosage forms such as creams and ointments as these products usually 
contain a large number of excipients including vehicles, surfactants, stabilisers, 
preservatives, and thickening agents (128). 
Vehicles alone can cause dramatic effects on the permeation of drugs, and even for 
dermatological products, vehicles can dramatically influence drug uptake into the skin 
(142). It is now becoming apparent that the manner in which vehicles influence 
transdermal drug delivery is different from the manner in which they affect local drug 
delivery to the skin (128). This is believed to be due to the simultaneous uptake of the 
vehicles and other formulation components into the skin, which can cause alterations in the 
skin integrity and changes in the microenvironment of the skin (142). 
2.1.3.6 Penetration Enhancers 
Chemical and physical approaches have been used to improve or enhance the permeation 
characteristics of drugs of choice (128). The chemical approach involves using certain 
chemicals in the formulation that improve drug permeation by modifying the 
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thermodynamic properties of the drug or by altering the skin integrity to make it more 
permeable. 
A confusing aspect of the chemical approach is that it is difficult to differentiate typical 
vehicle effects from typical enhancer effects, as the point at which a chemical becomes an 
enhancer has not been well defined. Even if a certain chemical is labelled as an enhancer 
in a given formulation, its effectiveness is highly influenced by the vehicle(s) used (128). 
It is the complex interaction between the biochemical constituents of the skin, the drug and 
the constituents of the donor vehicle that may enhance the permeation of the drug through 
the membrane, or retain it within the vehicle environment. 
2.1.4 Diffusion Boundary Layer Formation 
The drug concentration gradient is the driving force for diffusion and any increase in the 
drug concentration on the receptor side of the barrier would decrease the magnitude of the 
gradient and retard further permeation. In many cases of in vitro diffusion cell use, 
absolute sink conditions do not prevail for the entire experimental period because of 
accumulation of the permeant in the receptor phase. However, if this increase in 
concentration is not substantial then it may be assumed that sink conditions have not been 
violated. 
The characteristics of the mass transfer within the receptor chamber of the diffusion cell 
are determined by the nature of the liquid motion: either laminar or turbulent flow may 
exist dependent on the degree of fluid agitation. Laminar flow is uniform in character with 
little variation in the velocity of the fluid eddies throughout the chamber. Turbulent flow is 
irregular in direction and velocity, and mass transfer in these cases is by irregular fluid 
pulsations. In both cases, the properties of fluid flow at the membrane surface are 
important as the diffusant molecules that partition into the receptor fluid from the distal 
surface of the membrane must be rapidly swept away by the bulk fluid motion so that the 
concentration differential may be maintained across the barrier. 
In both flow conditions the velocity of the fluid will decrease in the layers adjacent to the 
membrane, and will be zero at the barrier surface. This layer of fluid near the membrane, 
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that is not agitated at the same rate as the bulk fluid, is termed the boundary diffusion layer 
and is generated by the viscous, frictional drag forces between one theoretical fluid layer 
passing over another. The rate of agitation is one of the primary determinants of boundary 
layer thickness. The greater the degree of agitation of the bulk fluid the greater will be the 
shearing stress on the fluid layers adjacent to the membrane, and a thinner boundary layer 
will result. Conversely, slow stirring of the chamber fluid will generate much thicker 
stationary diffusion layers with a more gradual decrease in the fluid velocity. Turbulent 
flow is generally regarded as more efficient than laminar flow in the dispersion of these 
relatively stationary fluid layers. The viscosity of the receptor fluid is equally important in 
determining the thickness of the diffusion layer. Only under conditions of optimal fluid 
agitation would the diffusion boundary layers in the receptor chamber of the diffusion cell 
be minimised and therefore, negligibly influence the overall resistance to mass transfer 
(46). 
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2.2 MEMBRANES FOR USE IN IN VITRO DIFFUSION EXPERIMENTS 
2.2.1 Biological Membranes 
2.2.1.1 Human Skin 
Human tissue would be the best medium to use in a diffusion cell so that appropriate 
extrapolation of conclusions to the in vivo situation could occur. Excision of the skin does 
not alter its permeability properties significantly, provided the stratum corneum remains 
intact, and several studies have shown that the stratum corneum performs similarly in vitro 
and in vivo even after several postmortal days (70,71). It should therefore be possible to 
design representative in vitro systems using excised human or animal tissue as a similarity 
between laboratory animal and human skin has been observed (72,73). 
The use of human skin for experimentation is not without problems. Its availability is 
limited and permeability varies greatly between specimens taken from the same or 
different anatomical sites of the same donor (27% variance in vivo and 43% in vitro), and 
greater variations (45% variance in vivo and 66% in vitro) are noted between specimens 
from different subjects of different age groups (74-76). Complicating these difficulties, 
metabolism and biotransformation of chemicals applied to the skin may continue for long 
periods after excision of the tissue from the donor and may be extensive in some cases 
(77). 
2.2.1.2 Animal Models 
Given the limited availability of human tissue and the fact that a number of percutaneous 
investigations may be too toxic to be carried out on living subjects, a number of animal 
models have been investigated for their usefulness in predicting percutaneous absorption 
kinetics. These animal models include mouse (53,80,81,83), hairless mouse (53,80,83-92), 
rat (53,73,80,93-96), guinea pig (80,97), rabbit (53,64,78,83,98,99), monkey 
(52,53,80,81,100), pig (53,79-81,94,178), snake skin and egg-shell membranes (80,101). 
The skin of experimental animals differs markedly from that of humans in features such as 
thickness and biochemical composition of the stratum corneum, and especially the 
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presence or density of hair follicles and glands (49). Furthermore it has been suggested 
that the lipid content of the skin is a major determinant in its barrier potential and that 
differences between species or between sites are due to varying lipid composition (40,51). 
Recently there has been considerable interest in the use of shed snake skin as a membrane 
for in vitro diffusion studies monitoring the release of a number of drugs from semisolid 
formulations (102-104,108-111,177,244). Shed snake skin has also been suggested as a 
membrane for the study of the effects of a number of penetration enhancers (112-120,244). 
Although shed snake skin is not a mammalian integument, many compounds penetrate 
snake skin and human stratum corneum at similar rates (102,103,172,179,180). Both shed 
snake skin (149) and human stratum corneum (150) are composed of keratinized proteins 
and lipids. Water permeation characteristics of snake skin are similar to those of human 
skin (136,151). 
In some countries it is particularly difficult to obtain human skin for in vitro 
experimentation and it is therefore important to have alternate biological or synthetic 
membranes which mimic human skin for diffusion experiments (111). In South Africa, 
shed snake skin is easily obtainable from the many snake parks present in the country. 
Since snakes moult periodically, a single animal can provide repeated sheds, thus 
eliminating inter-individual variability. Skins can be obtained without injury to the animal 
and do not have to be subjected to chemical or heat stress before use (80). The epidermis 
is shed as a large, intact sheet, thus a single snake skin can provide multiple samples (104). 
Shed snake skin is not a living tissue, can be stored at room temperature for relatively long 
periods and is easily transported. Stored or fresh skins appear to show no differences in 
permeability. Since snake skin lacks hair follicles, the problems associated with 
transfollicular routes of penetration, which may be significant in mammalian skins, can be 
avoided (80). 
Snakes shed their skin every two to four months, depending upon the species, age of the 
animal and quantity of food ingested. Skins are shed in different ways. This shedding has 
been observed for three species of snakes in a South African snake park. It was reported 
that the Naja melanoleuca (forest cobra) and the Bitis nasicomis (rhinoceros viper) rub 
their noses against a hard surface, normally a rock, to break the old skin. They then, with 
very gentle muscular contractions, loosen the whole skin and ease their bodies out of the 
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hole in front, leaving behind a complete shed skin. The Python sebae natalensis (African 
rock python), on the other hand, tends to rub its body against the rocks, thus the skin comes 
away in fragments (111). 
Shed snake skin is composed of two very different regions as depicted in figure 2.1. These 
comprise the scales which are separated by hinges. The scales are fairly rigid, whereas the 
hinge region is relatively elastic. The scales on the dorsal surface are much smaller than 
the scales on the ventral surface and, in addition, the size of the scales varies considerably 
between species. 
Unlike human stratum corneum, which consists of 10-20 layers of an alpha-keratin-rich 
intracellular layer and a lipid-rich intercellular layer (172), shed snake skin consists of 
three distinctive layers (113). These are the beta-keratin-rich outermost beta layer, alpha-
keratin- and lipid-rich intermediate mesos layer, and alpha-keratin-rich innermost alpha 
layer (149). Further, the mesos layer shows three to five layers of multilayer structure with 
cornified cells surrounded by intercellular lipids, which is similar to human stratum 
corneum. This mesos layer is also a major depot of lipids, and the mesos layer and alpha 
layer are considered to be the main barrier to water penetration through the skin (172,180-
186). 
Lipid compositions of shed snake skin and human stratum corneum are also similar, i.e., 
neutral lipids are a major lipid component in both skins and fatty acids, with carbon chain 
lengths of C 16 and C 18 predominant (172). Lipids are important components of the skin 
in controlling the permeability of compounds, and delipidization has been shown to 
increase water permeability through both shed snake skin and human skin (151) . 
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Figure 2.1 Diagrammatic representation of the transverse section of shed snake skin 
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Previous studies indicate that different snake species have been used as well as both dorsal 
and ventral skin. Some studies report which species of snake was utilised and whether 
dorsal or ventral skin was used in the experiments. Other studies did not report whether 
dorsal or ventral skin was used (103,108,112-114,118,121,244) and two studies did not 
indicate which species was used (116,117). This study addressed the diffusion 
characteristics of four different species of snake and investigated the differences between 
the dorsal and ventral skin sites as well as the orientation of the skin with respect to the 
semisolid formulation surface. 
It has been shown in an investigation involving the Naja melanoleuca (forest cobra), the 
Bitis nasicornis (rhinoceros viper) and the Python sebae natalensis (African rock python) 
that the most permeable is the python skin with dorsal skin being significantly more 
permeable than ventral skin. Cobra skin displayed intermediate permeability with dorsal 
and ventral skin producing identical results. Viper skin was found to be the least 
permeable with dorsal skin being more permeable than ventral skin. The apparent release 
constants obtained from regression analysis of the diffusion curves, displayed the same 
trend. The lag time was found to be very similar for python and cobra skins but virtually 
zero for viper skin (111). 
The same investigation found that the ventral skin of all three species is always thicker 
than the dorsal skin both in the scale and hinge regions. This was attributed to the fact that 
when the snake moves, the ventral surface is in contact with the ground. It would therefore 
have to be more robust than the dorsal surface. In addition, the hinge region was found to 
be considerably thinner than the scale region, especially in the forest cobra and rhinoceros 
viper. Generally, the ventral scales are much larger than the dorsal scales resulting in a 
much larger hinge:scale ratio for dorsal skin than for ventral skin. Since permeation 
appears to be more facile through dorsal skin, it may imply that diffusion occurs mainly 
through the hinge region of the skin (111). 
The study concluded that shed snake skin may be a useful membrane for comparing the 
diffusion of specific drugs from different formulations or the effects of different enhancers 
but care must be exercised when extrapolating to the in vivo situation since each species 
displays different permeation characteristics (111). 
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2.2.2 Synthetic Membranes 
The use of artificial membranes is common in laboratory percutaneous absorption studies. 
Synthetic membranes are not intended to mimic the barrier properties or the heterogeneous 
nature of the skin but, instead, to serve as predictive models for topical drug release (175). 
They are useful in preformulation studies designed to determine the leaving potential of an 
active drug from its vehicle and in ensuring batch-to-batch uniformity of the formulated 
topical vehicles (176). Furthermore, the stability and uniformity of synthetic membranes 
makes them desirable for use in diffusion experiments. 
The barrier potential of porous membranes is dictated by the probability of a diffusant 
molecule entering and diffusing through the pores. The only factor governing selectivity to 
diffusion would be the relative molecular size and shape. Conversely, aporous media 
appear to offer some rate-limiting factor to permeation and therefore may more closely 
simulate the diffusion through biological tissue. The barrier properties here generally 
relate to the solubility of the diffusant in the polymer matrix and partition coefficient 
between donor and membrane (54). 
2.2.2.1 Filter Membranes 
Porous filter membranes have seen relatively little usage in diffusion systems in 
comparison to the synthetic polymers. Generally, porous filter media appear to be most 
useful as a dividing medium or as supporting screens where the release rate of drug from 
the delivery system is under investigation, and not the transdermal kinetics of the 
permeant. In these cases the filter medium does not simulate the skin and provides no 
significant barrier to diffusant passage (55). 
2.2.2.2 Cellulose Media 
Cellulose is a relatively rigid structure consisting of glucopyranose rings combined by~-
1,4-inkages. This conformation allows only two types of movement in the chains: 
inversion of the pyranose ring or rotation around the glycosidic linkage (3). In addition, 
the cellulose chains exist in a partially crystallised form due to inter-chain hydrogen 
bonding (54). Commercial cellulose membranes have a cut off of 8000-15000 daltons for 
molecular dialysis and on purchase normally contain a number of softener, preservative 
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and plasticizer additives which may affect drug permeation depending on the membrane 
pre-treatment prior to experimentation. 
Cellulose acetate (dialysis) media have been extensively used in diffusion cell systems (56-
61). Generally, cellulose membranes are reported to be more permeable than biological 
membranes or aporous synthetic media (62) and are non-discriminatory to the 
characteristics of the diffusant molecule. 
2.2.2.3 Synthetic Polymers 
Diffusion of a molecule through continuous synthetic polymer is dependent on the 
frequency of void formation of sufficient size to accommodate the diffusant. Voids are 
formed by the random oscillation of polymer chains and the larger the diffusant species the 
greater the number of neighbouring polymer units which would have to move in a specific 
manner in order to generate a void of sufficient volume to accommodate the diffusant 
(46,66). 
Molecular flux through continuous polymer is analogous to flux through liquids, but in this 
case molecular voids are formed by the random oscillation of polymeric units. Hydrogen 
and other small molecules may require only monomeric unit displacements whereas larger 
diffusional species need cooperative oscillations, possibly involving polymer segments 
containing tens of units (66). The degree of bonding interaction between the polymer 
chains wiIl determine the rigidity of the matrix and thus, the propensity for hole formation 
and resultant permeability. Furthermore, crystallinity within the matrix generates regions 
of low diffusivity and the presence of solvents facilitates the oscillation of polymeric 
segments, both situations altering the overall permeability of the membrane (63,64). 
Crystallinity introduces regions of very low diffusivity relative to the diffusivity in the 
surrounding amorphous mass. At a minimum, solvent tends to facilitate the osciIlation of 
polymeric segments by reducing chain interactions (plasticization) and changing 
permeability. In the extreme, the solvent may become the diffusional medium (66). 
Silicone elastomer is above its glass transition point (point of appearance of crystallinity) 
at ambient temperature and, in addition, solvent is denied access by the physicochemical 
nature of the polymer, therefore these complexities are absent in this study. 
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Silicone polymers such as polydimethylsiloxane are lipophilic in nature and highly 
permeable to many non-ionic drugs which dissolve in the barrier matrix and diffuse across 
it (62,65,66). An important variable affecting the permeation process is the partition 
coefficient between donor or receptor vehicle and membrane, as is the polymer solubility 
of the drug. These two factors are highly dependent on structure and even small molecular 
modifications may greatly alter partitioning and solubility (63). 
Commercial products may contain additive fillers, such as 20-30% silica or graphite, to 
improve the membrane strength and their presence may increase the barrier potential to 
permeation. This filler is randomly orientated, non-uniform in size and is impervious to 
permeants but readily enters into adsorption interactions. Thus, permeation rates are 
generally lower through filled media (63,67-69) and lag times are increased (66). 
Generally, it is concluded that these fillers simply reduce the volume of polymer which is 
available for the steady state passage of permeating molecules and makes their diffusive 
path longer and more tortuous. 
Therefore, the most important parameters with regard to permeation appear to be polymer 
chain mobility (rigidity) and the solubility of the diffusant in the matrix, which influences 
the partition coefficient. Silicone membranes are considered the most useful of the 
synthetic media for use in diffusion cell systems. Its relatively inert, lipophilic nature 
makes it an ideal environment for partitioning and permeation of drugs while its aporosity 
provides some rate-limiting function to this process. 
2.2.3 Conclusions 
It is evident that no single animal or synthetic model can mimic percutaneous absorption in 
man for the diverse range of chemicals that are investigated for clinical and toxicological 
effects. A specific test system comprising membrane, diffusion cell type (105), cell 
receptor fluid, analytical procedure (106), agitation and temperature (107), must be 
established for each drug and delivery vehicle under investigation. 
Presently, biological membranes are used more extensively than synthetic membranes in 
laboratory diffusion systems. In addition, the comparison of results from different 
laboratories is difficult because of the plethora of different diffusion cells and experimental 
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protocols currently used worldwide. As the technology of polymer membranes and cell 
culture techniques improves, it may be expected that these media would become 
convenient standard membranes for use in topical drug delivery systems (80). 
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2.3 DIFFUSION CELL APPARATUS 
2.3.1 Introduction 
A number of experimental methods have been developed to investigate the percutaneous 
delivery of topically applied drugs in an attempt to isolate physical and chemical factors 
that govern drug absorption. In many instances the diverse experimental techniques tend 
to obscure absorption controlling factors and complicate inter-study comparisons. 
The benefits of utilising an in vitro cell system for the preliminary testing of drug diffusion 
in the laboratory are numerous. The environment, specific permeation parameters and 
variables may be controlled in an attempt to elucidate specific factors affecting the kinetic 
processes, prior to undertaking studies in human volunteers. The permutations of these 
variables that are selected for study will dictate the design and protocol of the experiment. 
Experimental design that allows the greatest number of variables and different variable 
permutations to be investigated by the same in vitro diffusion apparatus is highly desirable. 
Drug absorption factors which may require consideration when selecting an in vitro system 
include (152): 
1. The intrinsic diffusivity of the permeating molecule, its structure-activity relationship 
and its apparent diffusion coefficient. 
2. The route of penetration that will predominate during the experiment and the relative 
extents of drug binding and metabolism that will occur. 
3. The rate-limiting factor in the permeation process: drug solubilization and/or diffusion 
in the formulation, partitioning from the vehicle, diffusion through the test membrane 
or partitioning and removal by the receptor phase. 
4. The intrinsic barrier potential of the test membrane and the effects that vehicle 
components may have on its retardive properties. Hydration of the membrane may be 
important in this regard as may be the presence of penetration enhancers. 
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Inter-specimen variability between membranes of the same type may greatly influence 
experimental results. 
Several diffusion cell designs incorporating rate-limiting membranes have been reported in 
the literature, each design having specific features which it was hoped would overcome 
certain experimental limitations. Most designs share common features which include two 
chambers, one containing the donor vehicle and the other containing agitated receptor 
phase fluid, the two chambers being separated by the membrane under test. The 
appearance of the drug in the receptor phase (or diminution from donor phase) may then be 
analytically monitored as a function of time. The donor vehicle is assumed to expose the 
membrane to a constant concentration of the drug and the receptor phase is assumed to 
maintain sink clearance conditions for the permeant. It has been reported that a depletion 
of donor phase or an increase in receptor phase concentration not exceeding 10% does not 
significantly violate zero-order flux conditions or deviate from the initial thermodynamic 
driving force for diffusion (156). 
The influence of adequate receptor solvent agitation on the results obtained from in vitro 
diffusion experiments have shown that as stirring rate increased, the thickness of the 
unstirred boundary diffusion layer decreased and drug permeation rate increased. 
Moreover, if stirring increased sufficiently the rate of detected permeation would no longer 
be partially governed by the diffusion layer thickness (55,157). Many experimental 
observations are made when boundary diffusion layers represent a significant portion of 
the total barrier presented to the diffusing solute. The greater the portion of this 
representation the less accurate are the results obtained with respect to the membrane itself 
and the greater will be the deviation between in vitro and in vivo results. In some cases the 
existence of the diffusion boundary layer is acknowledged but is ignored in comparative 
work because of its uniformity throughout the experiments (54), or it is assumed to be 
negligible (158). This is acceptable as long as it is realised that calculation of the diffusion 
coefficient will include the contribution of the boundary layer barrier and thereby only 
yield an apparent diffusion coefficient value. 
Although several solvents have been used for the donor and receptor vehicles, the vast 
majority of the reported experiments use aqueous media because the assay of drugs in 
aqueous solution is facile by a number of techniques. However, drug solubility must be 
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considered when aqueous solvents are used. If the diffusant is only slightly soluble in the 
receptor fluid then it will not partition from the distal surface of the membrane and further 
diffusion will be retarded (159-161). The question of hydration should also be addressed 
when membranes are immersed for prolonged periods in aqueous vehicles. The effect that 
hydration may have on permeation appears to vary depending on the drug under 
investigation and membrane characteristics (75,162,163). On the other hand, the use of 
alcoholic or nonpolar organic solvents must in no way affect the biochemical composition 
of the barrier membrane (161). 
Although diffusion cells are manufactured with many different designs, there are two basic 
models that have been identified: one-chambered and two-chambered cells (153). Each 
type has its own use for skin absorption experiments. 
2.3.2 Two-Chambered Cell 
Researchers have used variations of the two-chambered cell for measuring the diffusion of 
a compound in solution from one side of a membrane to the other (154). A dose that is 
large enough to maintain constant concentration during the course of an experiment (an 
infinite dose) is added to one side of the diffusion cell, and the rate of diffusion across a 
concentration gradient into a solution on the opposite side of the membrane is determined. 
Usually, the solution on each side of the membrane is stirred to ensure that the 
concentration of test compound remains uniform throughout the experiment. Studies that 
compare absorption through membranes according to principles of Fick's membrane 
diffusion theory are usually conducted with these cells. The two-chambered cell is also 
useful for studying mechanisms of diffusion through membranes and for measuring 
membrane permeation (153). 
2.3.3 One-Chambered Cell 
The actual exposure of the membrane to substances that are absorbed usually occurs under 
conditions different from those simulated by the two-chambered cell. The amount of 
material applied to the surface of the membrane is frequently small (finite dose), and as 
permeation proceeds, a steady-state rate of absorption is not achieved. The surface of the 
membrane in this type of cell is frequently open to the environment. The membrane is not 
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excessively hydrated by continued exposure to an aqueous solution, as in the two-
chambered cell. The chamber beneath the membrane holds the receptor fluid, which is 
continually mixed with a magnetic stirring bar. Aliquots of the receptor fluid are removed 
through a side arm for analysis, and the rates of penetration through the membrane are 
determined (153). 
Infinite doses can also be applied to the membrane in the one-chambered cell for 
determination of steady-state absorption kinetics and lag times when semisolid 
formulations are applied to the membranes. In these investigations it is assumed that the 
drug concentration in the donor phase does not diminish significantly during the time 
course of the experiment. After the initial transient period of membrane saturation, and 
provided sink conditions are maintained, the concentration gradient across the membrane 
and the drug permeation rate should remain constant (153). 
In this experimentation the characteristics of the donor vehicle may vary greatly from the 
solutions used in the two-chambered cell design. A film of drug deposited by solvent 
evaporation, one of the numerous types of topical formulations, or even a transdermal 
delivery device, may be used as the drug source. Other benefits include the ability to 
control parameters of the donor compartment such as humidity, thereby simulating 
occluded or unoccluded clinical conditions. Additionally, the membrane may sequentially 
be treated with chemicals before or during exposure to the permeant to ascertain what 
effect they have on the retardative properties of the barrier medium (164-167). 
There are two basic designs of one-chambered cell: flow-through and static. 
2.3.3.1 Flow-Through Diffusion Cell 
A flow-through cell system was introduced to automate sample collection from a one-
chambered cell (82). The flow-through design also facilitates the maintenance of 
membrane viability because the physiological receptor fluid is continually replaced. 
Receptor fluid eluting from the diffusion cells is automatically collected in a fraction 
collector. Possibly the most important feature of flow-through cell design is the volume of 
the diffusion cell receptor, which must be small (less than O.5rn1) so that it can be properly 
flushed out during sample collection intervals with a manageable volume of receptor fluid. 
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Cells should be made of a material that does not bind or retain test compounds. Glass and 
teflon are preferred for construction of cells because they are inert. A glass window fitted 
in the bottom of the cell allows viewing of the receptor contents and thereby verifying the 
absence of air bubbles (153,156). 
2.3.3.2 Static Diffusion Cell 
Most of the static diffusion cells described in the literature are of similar design: a lower, 
agitated, solvent-filled receptor chamber with an inclined, stoppered, sampling side-arm. 
The receptor volume of the static one-chambered cell can vary with the diameter of the 
opening for the membrane specimen. Heated water is usually used to maintain a 
physiological temperature in the chamber leaving the flange at ambient temperature so that 
the donor vehicle is not heated, although there is some debate as to the appropriate 
temperature that will give the desired skin temperature (153). Frequently, glass cells 
require assembly where the membrane is mounted horizontally between the flanged edges 
of the lower chamber and the upper donor container, which are sealed with a metal clamp 
making the joint water-tight. Fluid is added to the cell to the level of the membrane, so 
that no hydrostatic strain is imposed on the medium, and any air bubbles which form may 
be expelled through the sampling port by tipping the cell. Magnetic stirring bars are 
usually used for mixing thereby avoiding unmixed regions directly underneath the skin. 
Finite-dose techniques and the design of a static one-chambered diffusion cell were 
described by Franz (155). The Franz cell is probably the most widely used diffusion cell 
and has been commercially available for many years (153). The cell has the normal 
bichamber arrangement but has a dumbbell-shaped receptor chamber (168). An 
un stoppered sampling port is connected to the upper segment of this compartment and only 
the central, cylindrical portion of the receptor chamber is surrounded by a thermostatically 
controlled water jacket. A stirrer bar in the lower, ellipsoid bulb generates agitation. 
Keshary and Chien (88,169) have summarised the shortcomings of the Franz cell after 
comparative evaluation, and Chien and Valia (170) have compared the hydrodynamics of 
this cell to their own design. They report that the architecture of the Franz cell does not 
provide adequate solution hydrodynamics, mixing efficiency and temperature control 
required for quantitative permeation evaluations. On the basis of these shortcomings 
35 
Keshary and Chien proposed a number of modifications to the Franz cell design which 
were adopted in this study (see figure 2.2). Their stoppered receptor compartment is a 
simple cylinder, shorter in height than the Franz design, completely enclosed by a water 
jacket and a star-head magnet is used to agitate the fluid. Equilibrium temperature 
maintenance, boundary diffusion layer thickness and solution mixing efficiency were 
substantially improved by these modifications. 
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Figure 2.2 Schematic of a modified Franz diffusion cell assembly 
An alternative to the vertical Franz-type cells is the USP tablet dissolution apparatus 
modified to accommodate a newly introduced accessory, the Enhancer cell. This 
dissolution cell is easy to load, and most laboratories have a USP dissolution apparatus. 
Furthermore, the apparatus allows variable paddle speeds, good temperature control and 
avoidance of air bubbles. 
An in vitro release study of triamcinolone acetonide from hydroalcoholic gel was 
conducted using a Franz vertical diffusion cell and a modified USP dissolution apparatus 
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(171). It was found that the release rate for triamcinolone acetonide from hydroa1coholic 
gel was slightly higher and diffusion coefficients more consistent based on release data 
obtained from the dissolution cells as compared with the vertical diffusion cells. 
Notwithstanding these relatively minor differences, both types of apparatus gave similar 
results. 
The European cell dissolution apparatus (187) is similar to the modified USP tablet 
dissolution apparatus. The diffusion cell consists of a support, a cover and a membrane. 
All parts of the apparatus that may come into contact with the topical formulation being 
examined or with the receptor medium are chemically inert and do not adsorb, react with 
or interfere with the topical formulation being examined. All metal parts of the apparatus 
that may come into contact with the receptor medium must be made from a suitable 
stainless steel or coated with a suitable material to ensure that such parts do not react or 
interfere with the receptor medium. No part of the assembly, including the environment in 
which the assembly is placed, contributes significant motion, agitation or vibration beyond 
that due to the smoothly rotating element. 
The support contains a central depression which acts as the reservoir for the trans dermal 
dosage form. The depth of the central reservoir is 2.6 mm, while the diameter may be 27 
mm, 38 mm, 45 mm or 52 mm; which corresponds to volumes of 1.48 ml, 2.94 ml, 4.13 ml 
and 5.52 ml respectively. The diameter chosen for this study was 38 mm. The cover has a 
central aperture, the diameter of which determines the surface area of the reservoir from 
which the topical formulation diffuses. The diameter of the aperture may be 20 mm, 32 
mm, 40 mm or 50 mm; which corresponds to surface areas of 3.14 cm2, 8.03 cm2, 12.56 
cm
2 
and 19.63 cm2 respectively. The diameter corresponding to the chosen support for this 
study was 32 mm with an aperture area of 8.03 cm2. The cover is held firmly in place 
above the support by four screws extending into the support base. 
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Figure 2.3 European Pharmacopoeia diffusion cell (187) 
The diffusion cell is assembled and placed into a cylindrical vessel with the diffusion 
surface facing upwards and parallel to the horizontal plane. The cylindrical vessel is made 
from borosilicate glass or other suitable transparent material, with a hemispherical bottom 
and with a nominal capacity of 1000 ml. The vessel has a flanged upper rim and is fitted 
with a lid that has a number of openings, one of which is central. The apparatus has a 
motor with a speed regulator capable of maintaining the speed of rotation of the paddle 
within ± 4% of 100 rpm. The motor is fitted with a stirring element which consists of a 
drive shaft and a paddle. The paddle is lowered to a depth corresponding to 10 ± 2 mm 
above the diffusion cell surface. The temperature of the receptor fluid is maintained at 
32 ± 0.5 dc. Evaporation is prevented by the fitted lid. Samples are taken from the 
cylindrical vessel at suitable time intervals. 
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Figure 2.4 Schematic of a modified European Pharmacopoeia diffusion cell assembly 
(187) 
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2.4 FORMULATION ASPECTS 
2.4.1 Introduction 
Topical delivery can be defined as the application of a drug-containing formulation to the 
skin to directly treat cutaneous disorders or the cutaneous manifestations of general 
disease, with the intent of confining the pharmacological or other effect of the drug to the 
surface of the skin or within the skin. Topical activities mayor may not require intra-
cutaneous penetration and deposition, and while systemic absorption may be unavoidable, 
it is always unwelcome (144). Ointments and creams dominate the systems for topical 
delivery, but gels, foams, sprays, medicated powders, solutions, lotions (fluid emulsions 
and suspensions), and medicated adhesive systems are also in use. 
Regional delivery, by contrast, involves the application of a drug to the skin for the 
purpose of treating diseases or alleviating disease symptoms in deep tissues beneath the 
application, where the intent is to effectuate or accentuate the pharmacological actions of 
the drug beneath and around the site of application (144). A selectivity of action over that 
which can be achieved by the systemic administration is sought. Regional delivery is 
accomplished with traditional ointments and creams and also large adhesive patches, 
plasters, and poultices. 
Transdermal delivery involves the application of a drug to the skin to treat systemic disease 
and is aimed at achieving systemically active levels of the drug. While traditional dosage 
forms can be employed in this kind of therapy, adhesive systems of precisely defined size 
are the rule. Here, percutaneous absorption with appreciable systemic drug accumulation 
is absolutely essential. Local build-up is unavoidable as the drug is forced through the 
relatively small diffusional window defined by the contact area of the patch. 
Consequently, high and potentially irritating or sensitising concentrations of a drug in the 
viable tissues underlying the patch are preordained by the nature of the delivery process 
(144). 
The functional features of dermatological systems such as ointment, creams, and gels stand 
in stark contrast with those of transdermal delivery systems. Most topical applications are 
left open to the atmosphere with an estimated thickness of an application ranging between 
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10J...lm and 30J...lm in ordinary circumstances. Their area to thickness ratios are large, thus 
any volatile materials contained within the topical film will invariably evaporate rapidly 
following its application. Since ointments are made mostly of high molecular weight 
hydrocarbons of low volatility, these are presumed to be relatively compositionally stable 
upon application, whereas creams, gels, topical solutions, and lotions are completely 
different in this regard with as much as 90% of the system's composition being appreciably 
volatile. Evaporation of these ingredients begins immediately upon application of the 
dosage form, and it continues until all of the volatile substances are exhausted. 
Extraordinary physicochemical changes accompany the evaporative concentration of the 
formula, and, as a consequence, the thermodynamic activity of every ingredient in a 
topically applied film is continually varying. Since it is the thermodynamic activity of a 
drug that exists at the surface of the skin which determines the partitioning of the drug into 
the skin, and since this is time-dependent in ways related to compositional changes, topical 
delivery is seldom a steady-state process for any appreciable duration (144). 
The most common pharmaceutical vehicles for topical ibuprofen used in clinical practice 
are gels, creams and aerosol quick-break foams. The extent to which ibuprofen is released 
from these vehicles is closely related to the solubility of the drug in the vehicle, the particle 
size of the drug, the occlusivity of the vehicle and the presence of penetration enhancers. 
2.4.2 Vehicles 
The percutaneous absorption of a drug is frequently an extremely inefficient process and 
the importance of the vehicle into which the drug is incorporated is recognised. The 
vehicle should, to the largest possible extent, facilitate the migration of the drug to the 
target site so as to allow the drug to exert its pharmacological effect. The ideal vehicle 
should be cosmetically acceptable, physically stable, physiologically inert and provide an 
environment in which the drug is stable and from which the drug in low concentrations is 
readily released. Maximisation of the release and penetrability of the drug, without 
unfavourably altering other relevant vehicle properties, should therefore be a general goal 
in topical vehicle design (122-126). 
The in vitro release of drugs from topical vehicles is a function of the solubility of that 
drug in both the vehicle and its surrounding medium. The drug must be sufficiently 
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soluble in a non-aqueous vehicle to allow for its release into an aqueous medium but not so 
soluble as to remain in that vehicle preferentially. If the drug is insoluble in its vehicle, 
only the drug particles available at the surface of the vehicle apparently dissolve into an 
aqueous medium. If the drug is partly soluble in the vehicle, it seems to dissolve and 
diffuse throughout the medium as it dissolves from the surface and then returns to the 
surface for release into the surrounding medium (124). 
The design of a vehicle for topically administered drugs should take into consideration 
general formulation aspects, the physical characteristics of the drug and the skin barrier, as 
well as the biophysics of skin transport. It is important to bear in mind that a vehicle that 
provides good release of one drug may not be suitable for another drug (122). 
2.4.2.1 Liquid Preparations 
Such systems for external application to the skin include simple soaks or baths, liniments, 
lotions, paints, varnishes, tinctures, and eardrops. Usually, these formulations are 
physicochemically simple and pose few difficulties to the prediction of their abilities to 
deliver drug to the skin once account has been taken of evaporation. Among the most 
complex are the micellar systems consisting of solutions of surface active agents in which 
the surfactants equilibrate between the monomer and micellar pseudophases (143). 
2.4.2.2 Simple Suspensions 
Simple suspensions may be fluid, gel-like, or semisolid and hydrophilic or hydrophobic. A 
gel-like system may consist of entangling polymer chains, adjuvant crystals, and solid drug 
particles in equilibrium with dissolved molecules at saturation. The dissolved medicament 
may be in free solution between the polymer chains, bound (usually reversibly) to the 
polymer chain, or adsorbed at the surface of non-drug solid. The excess drug provides the 
ultimate source, which, as molecules leave the vehicle to penetrate the skin, dissolves to 
replenish free and bound molecules and keeps the chemical potential at the maximum for a 
saturated system (143). 
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2.4.2.3 Gels 
A gel may be defined as a solid or semisolid system of at least two constituents, consisting 
of a condensed mass enclosing and interpenetrated by a liquid. Gels may be classified as 
either two-phase or as single-phase systems. The gel structure in a two-phase system may 
consist of floccules of small particles which are not always stable and may be thixotropic, 
forming semisolids on standing and becoming liquids on agitation. On the other hand, a 
gel may consist of macromolecules existing as twisted matted strands where the units are 
often bound together by stronger types of van der Waals forces so as to form crystalline 
and amorphous regions throughout the entire system. These gels are considered to be one-
phase systems since no definite boundaries exist between the dispersed macromolecules 
and the liquid (46). 
2.4.2.4 Emulsions 
Emulsions may be mobile lotions or semisolid creams. Essentially an emulsion is a 
heterogeneous system containing two immiscible phases: an aqueous or hydrophilic phase 
and a lipid or oil phase. If the mixture is one of hydrophilic droplets dispersed in oil, it is 
referred to as a water-in-oil (w/o) emulsion; the reverse is an oil-in-water (o/w) system. 
2.4.2.4.1 Oil-in-Water Emulsions 
Topical o/w creams ("vanishing" creams) rub into the skin and disappear with little or no 
trace of their former presence. In the preparation of dermatological o/w creams, mixed 
emulsifiers of the surfactant/fatty amphiphile type, in which the amphiphile is usually a 
long-chain acid or alcohol, are often employed. The water-soluble surfactant may be 
anionic, cationic, or nonionic. Combining a surfactant with a fatty amphiphile in the 
correct ratio produces a powerful emulsifying blend of the o/w type, with superior 
stabilising and thickening properties (143). 
2.4.2.4.2 Water-in-Oil Emulsions 
Water-in-oil emulsions provide a wide range of consistencies depending on the 
components in the oil and aqueous phase and their relative proportions, the emulsifier 
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blend, and various auxiliary agents. Oily creams contain w/o emulsifying agents, typically 
wool fat, wool alcohols, fatty acid esters of sorbitan, or the salts of fatty acids with a 
divalent metal such as calcium (143). 
It has been found that the vehicle has a substantial influence on the hydration of the skin 
barrier, with greases and oils being the most occlusive types of vehicle and consequently 
inducing the greatest degree of hydration. The inclusion of a surfactant into these vehicles 
results in water-in-oil emulsions which induce less hydration than greases and oils. Oil-in-
water emulsions, formed by an increase in the water/oil ratio, induce the lowest degree of 
hydration (124). It should be noted that greases and oils cause hydration by preventing 
evaporation of moisture from the skin whereas the emulsions both wet the skin and have 
varying degrees of occlusivity. The onset of hydration due to the former will therefore not 
be as rapid. 
2.4.2.5 Aerosol Quick-Break Foams 
The quick-break aerosol foam has the advantages of high activity (ibuprofen is in solution), 
ease of application, controlled dosage from a metering valve, economy in use and 
suitability for smooth or hairy skin. 
2.4.3 Penetration Enhancers 
Penetration enhancers utilised in ibuprofen formulations are propylene glycol, alcohol and 
possibly lower molecular weight polyethylene glycol (the molecular weight was not 
reported in the formulation composition). Evidence for the effects in promoting skin 
penetration of such solvents as propylene glycol and ethanol is conflicting as, in many 
instances, the liquids simply function as cosolvents to produce saturated or nearly saturated 
solutions of the active ingredient, thereby maximising the thermodynamic activity of the 
penetrant (145). In addition to affecting drug solubility in the vehicle, cosolvents may alter 
the structure of the skin and modify the penetration rate. Moreover, the use of a cosolvent 
in combination with a potential penetration enhancer may offer synergistic enhancement 
(146,147). 
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Ethanol and other volatile solvents initially build up a high concentration gradient of the 
drug on the skin surface. However, as a result of progressive evaporation of the solvent, 
the residual drug will precipitate and the absorption process will be interrupted. In general, 
higher molecular weight polyethylene glycols do not penetrate the skin and may form 
hydrogen bonds with penetrants, thus reducing the therapeutic activity of the compound 
and penetration rate. Propylene glycol appears to aid penetration best when combined with 
surfactants (145). 
2.4.4 Surfactants 
Surfactants are often included in pharmaceutical formulations as emulsifying agents. 
While penetration is poor, there is evidence that anionic and cationic agents do penetrate 
the skin, with anionics penetrating best followed by cationics and nonionics (124). 
The factor determining whether a nonionic surfactant will increase the absorption rate 
appears to be the configuration of the surfactant molecule rather than the hydrophilic-
lipophilic balance or surface activity. Where the surfactant has several long hydrophilic 
chains (more than five ethylene oxide units for example) rather than a single or several 
short ethylene oxide chains, drug absorption is not increased. This indicates that the 
effectiveness of the surfactant is due to the ease with which the surfactant molecules 
penetrate lipid membranes (124). 
The only surfactant encountered in the ibuprofen formulations was that of a 
polyoxyethylene fatty acid ester which is classified as a hydrophilic nonionic surfactant 
(3). This surfactant was present in both cream formulations. It has been shown that the 
addition of a polyoxyethylene fatty acid ester to a 4% w/w sodium carboxymethylcellulose 
gel improved the permeation parameters of ibuprofen through a standard cellophane 
membrane as compared to a control gel (174). Gels containing a polyoxyethylene fatty 
acid ester exhibited a higher release rate and significantly decreased lag time as compared 
to the control gel. 
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CHAPTER THREE 
THE IN VITRO ANALYSIS OF IBUPROFEN 
3.1 ANALYTICAL METHOD DEVELOPMENT 
3.1.1 Introduction 
A suitable analytical technique for ibuprofen should be able to quantify the drug and be 
stability indicating. The ideal assay should be precise, accurate, sensitive, rapid and 
specific. It should be capable of processing small volumes, be inexpensive and simple to 
perform. 
Many analytical procedures for the determination of ibuprofen have been reported 
including methods employing paper chromatography (189), gas chromatography (190-
194,201) gas chromatography-mass spectroscopy (195), and hplc techniques (196-213). 
Other quantitative procedures include electron and nuclear magnetic spectroscopy and 
infrared and ultraviolet spectrophotometry (214,215). 
Proprietary topical preparations may not contain the exact concentration of drug as 
specified on the label. This could be due to factors such as overage addition by the 
manufacturer, degradation or adsorption onto the inner surface of the container. If these 
formulations are accepted as label strength, misleading conclusions regarding the drug 
release characteristics of the vehicle may be drawn from the results of in vitro or in vivo 
assays. Discrepancies in performance may be due to drug concentration differences. It is 
therefore imperative that a reliable, analytical technique be available so that the exact drug 
content of all formulations used in diffusion studies may be measured. Appendix I lists the 
exact drug content of the formulations used in this study. No significant difference, 
evaluated at a 95% confidence interval, was found between the different drug 
concentrations as specified on the labels of the formulations. Only in this manner may 
conclusions be made from flux data with some degree of validity and confidence (152). 
Of all the possible analytical techniques, hplc has the required sensitivity, selectivity and 
versatility to provide fast and efficient drug analysis for formulation assessment. 
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3.1.2 Principles of High Performance Liquid Chromatography 
The feature that distinguishes chromatography from most other physical and chemical 
methods of separation is that two mutually immiscible phases are brought into contact; one 
phase is stationary and the other mobile. A sample introduced into a mobile phase is 
carried through a column containing a distributed stationary phase. Molecules in the 
sample undergo repeated interactions between the mobile phase and the stationary phase. 
At the end of the process, separated components emerge in order of decreasing interaction 
with the stationary phase. Interaction between the phases exploits differences in the 
physical and/or chemical properties of the components in the sample (188). 
Hplc is able to separate macromolecules and ionic species, labile natural products, 
polymeric materials, and a wide variety of other high molecular weight polyfunctional 
compounds. With an interactive liquid mobile phase, a parameter is available for 
selectivity in addition to an active stationary phase. Chromatographic separation in hplc is 
the result of specific interactions of molecules with both the stationary and mobile phases. 
Hplc offers a variety of stationary phases, which therefore allow a variety of these selective 
interactions and greater possibilities for separation. Sample recovery is usually 
quantitative (barring irreversible adsorption on a column), and separated sample 
components pass through unchanged (188). 
The stationary phase of the hplc system may be either a totally porous particle (or 
macroporous polymer) or a superficially porous support (porous layer beads or pellicular 
supports). Either of these types may have a polymer bonded to its surface. Molecules 
separated by these adsorbent packings are retained almost exclusively on the internal 
surface of the pores of the particles because only a small fraction of the active area is found 
on the outside of the particles (188). 
Knowledge of the molecular structure of the sample components can be very helpful in 
selection of a liquid chromatographic method. A general guide for the choice of a method 
is shown in table 3.1. 
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METHOD PREDOMINANT MECHANISM 
Liquid-solid or adsorption Adsorption on surface 
Liquid-liquid Partition between liquid phases, one mobile 
and the other stationary 
Bonded phase Partition and/or adsorption between mobile 
and bonded phases 
Ion pairing Separation of ion pairs between mobile and 
bonded phases 
Ion exchange Exploitation of charge by adsorption on fixed 
ionic site via cation or anion exchange 
Steric exclusion Exploitation of size via diffusion into pores 
by molecules able to enter 
Affinity Use of structure of immobilised ligand to 
bioselectively bind the desired protein 
Table 3.1 Liquid Chromatographic Methods 
The partition technique in its various forms is the most widely used mode in hplc and 
comprises nearly half of all liquid chromatographic methods described in the literature. 
This technique is the most likely to provide optimum retention and selectivity when 
compounds have a predominant aliphatic or aromatic character (188). 
Partition chromatography comprises a hydrophobic bonded packing, usually with an 
octadecyl (C-18) or octyl (C-8) functional group and a polar mobile phase and often a 
partially or fully aqueous mobile phase. Polar substances prefer the mobile phase and elute 
first. As the hydrophobic character of the solutes increases, retention increases. Generally, 
the lower the polarity of the mobile phase, the higher is its eluent strength. Hydrocarbons 
are retained more strongly than alcohols, with water as the weakest eluent. Methanol and 
acetonitrile are popular solvents because they have low viscosity and are readily available 
with a high degree of purity. Eluents intermediate in strength between these solvents and 
water are usually obtained by preparing mixtures (188). 
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3.1.3 Experimental 
3.1.3.1 Reagents 
All chemicals used were at least of analytical reagent grade. Acetonitrile and methanol 
(Burdick and Jackson Laboratories, Muskegon, Michigan, USA) were of hp1c grade. 
Ibuprofen (batch IBU9905390) was obtained from Shasun Chemicals and Drugs, Ltd. 
(Pondicherry, India). The sodium hydroxide pellets were obtained from Riedel-deHaen 
(Germany) and the orthophosphoric acid (85%) was obtained from Saarchem-Holpro 
Analytic (Pty.) Ltd., (Krugersdorp, South Africa). 
Water used for buffer preparation, extraction and chromatography was initially purified by 
a reverse-osmosis Milli-RO 15 Water Purification System (Millipore, Bedford, MA, USA) 
that consisted of a Super-C carbon cartridge, two Ion-X ion exchange cartridges and an 
Organex-Q cartridge. The water was filtered through a 0.22 J..lm Millipak stack filter prior 
to use. 
3.1.3.2 High Performance Liquid Chromatographic System 
The hp1c system used consisted of an IsoChrom Isocratic pump, a Spectra 100 UV -Vis 
detector and a Spectra-Physics DataJet integrator all from Spectra-Physics Inc. (California, 
USA). Samples were introduced into a 20 J..lI fixed loop injector using a 100 J..lI syringe 
(Scientific Glass Engineering, Australia). The analytical column was a 4.0 mm x 250 mm 
stainless-steel column, packed with Waters Sherisorb 5 J..lm octadecylsilane (C-18) material 
(Waters Corporation, Massachusetts, USA). 
3.1.3.3 Ultraviolet Detection 
Optical detectors based on ultraviolet-visible absorption are the most commonly used hp1c 
detection systems. Three types of absorption detectors are available: a fixed-wavelength 
detector, a variable-wavelength detector, and a scanning (in real time) wavelength detector. 
A variable-wavelength detector was used in the hp1c method developed for the analysis of 
ibuprofen. 
49 
A variable-wavelength detector offers a range of wavelengths from 190 to 600 nm, which 
permits a wavelength to be chosen where the solute absorbance is maximal and little 
interference is observed from additional solutes or the mobile phase. The absorption 
maximum (Amax) of ibuprofen was measured at 222 nm. Published methods for the 
analysis of ibuprofen vary considerably, utilising wavelengths from 214 to 263 nm, but 
many of these methods are optimised for the detection of more than one compound. 
3.1.3.4 Column Selection 
The choice of an analytical column is based on physical properties of the molecule, such as 
molecular mass, solubility and ionic character (188). Table 3.2 shows silica-based column 
packing material for partition chromatography. 
SAMPLE COLUMN PACKING 
Low/moderate polarity (soluble in aliphatic Bonded C-18 
hydrocarbons) 
Moderate polarity (soluble in methyl ethyl Bonded C-8 
ketone) 
High polarity (soluble in lower alcohols) Bonded C-2 
Table 3.2 Silica-based column packing material for partition chromatography 
Column packings can be described in terms of their chemical composition, whether silica, 
alumina, or carbon. The most commonly used adsorbant column packing material is silica 
particles, although alumina columns find applications in special situations. 
Many hplc separations are performed on columns with an internal diameter of 4-5 mm. 
Such columns provide a good compromise between efficiency, sample capacity, and the 
amount of packing and solvent required. Column packings feature particles that are 
uniformly sized and mechanically stable. Particle diameters commonly lie in the range 5-
10 /..lm. The smaller the microparticle, the greater the surface area resulting in a greater 
number of sites available for interactions, therefore, the better the resolution of the sample 
and the greater the sensitivity of the analytical method. Smaller particle sizes give more 
theoretical plates and better sensitivity, but higher backpressure than the larger particles. 
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The number of theoretical plates is a quantitative measure of the efficacy of a 
chromatographic system (188). 
The most commonly used column previously reported for the analysis of ibuprofen was 
octadecasilyl, C-18 (144,197,199,205-207,212,217-218). All columns used in this study 
were partition hplc columns. 
3.1.3.5 Mobile Phase Selection and Preparation 
The relative extent of the three-way interaction between the molecule, the stationary phase 
and the mobile phase will determine the efficiency and efficacy of the method used. If the 
molecule is highly soluble in the mobile phase, it will undergo limited partitioning onto the 
stationary phase, and retention times will be short. Conversely, if the molecule displays 
limited solubility in the mobile phase, it will partition into the stationary phase and thus 
result in a longer retention time. The pH of the aqueous component of partition systems is 
capable of modifying the retention time of weak acids and bases, as the un-ionised species 
is retained for a longer period of time because it is less polar. The use of organic modifiers 
in predominantly aqueous mobile phases will also alter the retention characteristics of the 
molecule. The choice and amount of modifier required will depend on the properties of the 
molecule and the stationary phase (219). Mobile phases with pH values outside the range 
of 3 to 9 may interact with the selected stationary phase, thus altering its properties or 
integrity. This interaction occurs via hydrolysis of the bonded phase or dissolution of the 
silica (219). The mobile phase must not interfere with the detection ofthe molecule, 
particularly when using uv detection. Many solvents exhibit some degree of uv absorbance 
at lower wavelengths, but wavelengths above 210 nm have been used with limited 
interference. It is important that the uv cut -off values for the solvents used are known and 
evaluated (219). Water and acetonitrile, the two solvents used in the study, have cut-off 
values at 195 nm. 
The effect of the mobile phase on the hplc system must also be considered. All mobile 
phases should be filtered through at least a 2 Ilm filter and degassed prior to use. This 
prevents the accumulation of particulate matter in the system with the resulting increase in 
backpressure. The presence of air may interfere with detection as well as cause pressure ,. 
fluctuations if caught in the pump. All solvents used should be chemically pure to ensure. ' 
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that no build up of impurities on the column or in the system occurs, and that no impurities 
interfere with the analysis. The viscosity of the solvent can influence backpressure. More 
viscous solvents and solvent combinations generally give rise to higher backpressures. 
High concentrations of buffer salts are also undesirable as there is a potential for 
precipitation with subsequent damage to pump seals and pistons and blockages with 
consequent increases in backpressure (219). 
The initial mobile phases used were based on those published or were modifications of 
these. The mobile phases used during development and the corresponding retention times 
are reported in table 3.3. 
MOBILE PHASE COMPOSITION RETENTION TIME REFERENCE 
Acetonitrile:O.Ol M Phosphate buffer (pH 3.0) No peak eluted by 35 144 
50:50 minutes 
Acetonitrile:0.02 M Phosphate buffer (pH 4.0) No peak eluted by 35 197 
40:60 minutes 
Methanol:Water (pH 3.3 adjusted with 22.9 minutes 207 
concentrated phosphoric acid) 
65:35 
Methanol:Water plus 1 m1 concentrated 26.3 minutes 212 
phosphoric acid per litre 
65:35 
Acetonitrile:Water (pH 2.0 adjusted with No peak eluted by 35 217,218 
concentrated phosphoric acid) minutes 
55:45 
Acetonitrile:0.04 M Phosphate buffer (pH 7.0) 6.3 minute, sharp peak, 211 
30:70 well resolved from 
solvent front 
Table 3.3 Effect of mobile phase on ibuprofen retention time 
As can be seen from table 3.3 a mobile phase comprising acetonitrile and 0.04 M 
phosphate buffer (pH 7.0) in a ratio of 30:70 gave sharp peaks at a retention time of 6.3 
minutes, which ensured good resolution from the solvent front. Two other mobile phases 
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yielded ibuprofen peaks at 22.9 and 26.3 minutes that were resolved from the solvent front. 
These retention times are too long for multiple sample analysis. 
3.1.3.6 Guard Columns 
To prolong the life of analytical columns, guard columns are often inserted ahead of the 
analytical column where they act as both physical and chemical filters. A Spheri-5 RP-18, 
5 Jl30 x 4.6 mm guard column (Perkin Elmer, Norwalk, USA) was necessary in order to 
filter contamination arising from formulation components as well as the biological 
membranes used. Guard columns are relatively short (usually 5 cm) and contain a 
stationary phase similar to that in the analytical column. They protect the analytical 
column from particulate contamination that arises from a contaminated mobile phase or 
from degrading sample-injection valves (188). 
Samples were loaded onto the analytical column, both with and without the guard column 
in line, and it was confirmed that the guard column made no significant contribution to 
dead volume or extra column effects. Guard columns are by design expendable and were 
periodically replaced when they were seen to have lost efficiency or caused backpressure 
in the system to rise. 
3.1.3.7 Preparation of Stock Solutions 
Approximately 100 mg of ibuprofen was accurately weighed into an A-grade 100 ml 
volumetric flask and made up to volume with hplc grade water or 0.2 M phosphate buffer 
(pH 7.2) prepared with hplc grade water. Standards ranging in concentration from 10 to 
150 Jlg/ml were prepared by serial dilution of this stock solution. 
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3.1.4 Optimisation of the Chromatographic Conditions 
3.1.4.1 Detector Wavelength 
The wavelength at which maximum absorption of ibuprofen occured (Amax) was found 
experimentally to be 222 nm. Some published methods have used alternative wavelengths 
(199,216), but detection in this region has been employed by the majority of investigators 
(144,197,205-207,212,217,218), and it was shown to be suitably sensitive for the purposes 
of this in vitro study. The effect of different wavelengths on the peak area representing 
maximum absorption of ibuprofen was investigated. As expected, peak area was affected 
by the wavelength used. The data are listed in table 3.4. 
CONCENTRATION 214nm 220nm 222nm 254nm 
(~ml) 
26.6 85.5 96.2 100 18.0 
53.2 86.7 92.1 100 21.3 
79.8 88.6 98.1 100 18.8 
133 86.9 94.5 100 16.4 
MEAN 86.9 95.2 100 18.6 
STANDARD 2.3 2.6 0 2.0 
DEVIATION 
%RSD 2.6 2.7 0 10.7 
Table 3.4 Effect of wavelength on the peak area of ibuprofen 
Results are shown as a percentage of peak area obtained with the 222 nm wavelength. The 
results indicate that absorption was maximal at 222 nm, with decreasing absorbance 
through 220 nm, 214 nm and 254 nm. Based on the results of this experiment 222 nm was 
chosen as the wavelength of detection. 
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3.1.4.2 Choice of Column 
A C-18 column was selected for the analysis of ibuprofen. Ibuprofen is a weak acid and is 
soluble in the aqueous-organic mobile phase combination, thus retention times are 
expected to be short with a non polar stationary phase, as ibuprofen will partition 
preferentially into the mobile phase. 
3.1.4.3 Mobile Phase Composition 
Methods to improve the mobile phase are numerous and include slight variations of pH, an 
increase or decrease of ionic strength and changes in the amount of modifier in the mobile 
phase. In order to determine an optimum mobile phase system, the organic phases, various 
buffer compositions, and different ratios of organic phase to aqueous phase were varied. 
Ionisation control by means of a buffer was considered when the drug appeared to be 
poorly retained with weakly eluting mobile phases. Different pH values and 
concentrations of salts (table 3.3) were tested until a suitable retention time and 
symmetrical peaks were obtained. A mobile phase comprising acetonitrile and 0.04 M 
phosphate buffer (pH 7.0) in a ratio of 30:70 gave sharp peaks at a retention time of 6.3 
minutes, which ensured good resolution from the solvent front, and therefore was selected 
for method validation (211). 
The buffer solution was prepared by accurately pipetting 2.5 ml of 85% orthophosphoric 
acid into a 11 A-grade volumetric flask and made up to volume with hplc grade water. 
The pH was then adjusted to 7.0 using sodium hydroxide pellets. A Crison pH meter 
(Crison, LASEC, South Africa) was used for pH measurements. The buffer solution was 
then combined with acetonitrile and filtered through a 0.45 /lm filter (Millipore, Maryland, 
USA) before use. 
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3.1.5 Chromatographic Conditions 
The optimal chromatographic conditions established during the method development were: 
Mobile Phase 
Flow Rate 
Detection Wavelength 
AUFS (Attenuation) 
Injection Volume 
Retention Time 
Temperature 
3.1.6 Conclusion 
Acetonitrile:0.04 M Phosphate Buffer (pH 7.0) 30:70 
1.0 ml/min 
222nm 
0.05 
20 f.ll 
6.3 minutes 
Ambient 
The effects of altering system variables on the elution of ibuprofen were established in 
these preliminary investigations. By optimising the choice of mobile phase, detection 
wavelength and analytical column, an hplc method which provided well resolved 
symmetrical peaks, suitable retention times and minimal baseline noise was developed. 
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3.2 METHOD VALIDATION 
3.2.1 Introduction 
One of the most important aspects of method development is the validation of the method. 
Validation of an analytical method is the process by which it is established that the 
performance characteristics of the optimised method meet the requirements for the 
intended analytical applications. Performance characteristics are expressed in terms of 
analytical parameters (3). 
Laboratories must perform method validation in order to be in compliance with Food and 
Drug Administration (FDA) regulations. The FDA designated the specifications in the 
USP as those legally recognised when determining compliance with the Federal Food, 
Drug and Cosmetic Act. For method validation the analytical parameters are precision, 
accuracy, limit of detection, limit of quantitation, specificity, linearity and range, 
ruggedness and robustness. The International Conference on Harmonisation (ICH) stated 
the validation characteristics somewhat differently as precision, accuracy, limit of 
detection, limit of quantitation, specificity, linearity, range, robustness and system 
suitability. Analytical parameters considered in the validation of the method used in this 
study are specificity, linearity, precision, limit of quantitation, limit of detection, accuracy 
and bias, and robustness. 
Once the chromatographic conditions have been optimised with respect to detector 
wavelength, choice of column and mobile phase composition, an attempt should be made 
to provide analytical figures of merit which are needed to meet the assay requirements, i.e., 
the required detection limits, limits of quantitation, accuracy and precision of quantitation 
and specificity must be defined. Results obtained during the validation procedure must be 
evaluated against the goals of the analysis set forth by the analytical figures of merit. This 
evaluation may reveal that additional development and optimisation are needed to meet 
some of the initial method requirements. 
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3.2.2 Accuracy and Bias 
Accuracy is the measure of exactness of an analytical method, or the closeness of 
agreement between the measured value and the value that is accepted either as a 
conventional, true value or an accepted reference value. Accuracy is expressed as percent 
error. Bias assesses the influence of the analyst on the performance of the method (220). 
To document the accuracy and bias, the ICH guideline on methodology recommends 
collecting data from nine determinations over three blinded concentration levels covering 
the specified range. Three replicate determinations of each of three concentration levels 
were used. The measurements were performed in consecutive and non-consecutive 
sequences (220). The percent error obtained during the determination of blinded 
unknowns is shown in table 3.5. 
CONCENTRATION MEAN DETERMINED STANDARD PRECISION PERCENT 
(J.l.glml) CONCENTRATION DEVIATION (% RSD) ERROR 
(J.l.glml) (0=3) 
103.3 107.4 1.2 1.1 -3.9 
51.7 50.4 0.8 1.6 +2.4 
25.8 26.1 1.2 4.6 +0.9 
Table 3.5 Percent error obtained during the determination of blinded unknowns 
The figures of merit for acceptable accuracy were taken as less than or equal to 10% 
relative standard deviation and less than or equal to 10% percent error (222). The 
analytical method was therefore deemed to be acceptable in terms of accuracy and bias. 
3.2.3 Precision 
Precision is the measure of the degree of repeatability of an analytical method and is 
expressed as the percent relative standard deviation for a statistically significant number of 
samples. According to the ICH, precision should be performed at three different levels: 
repeatability, intermediate precision, and reproducibility. 
58 
3.2.3.1 Repeatability 
Repeatability refers to the results of the method operating over a short time interval under 
the same conditions (inter-assay precision). It is an expression of the degree of variation 
arising during replicate assays performed consecutively and non-consecutively, but on the 
same day. Repeatability should be determined from a minimum of nine determinations 
covering the specified concentration range of the procedure (220). The percent relative 
standard deviation obtained from three replicate determinations of each of four 
concentration levels is shown in table 3.6. 
CON CENTRA TION MEAN PEAK STANDARD PRECISION 
(J.LgIml) AREA (n=3) DEVIATION (%RSD) 
125.3 1750108 20861 1.2 
12.5 211779 14067 6.6 
6.3 98711 2533 2.6 
1.3 23304 671 2.3 
Table 3.6 Repeatability with respect to four concentrations 
The figures of merit for acceptable precision were taken as less than or equal to 10% 
relative standard deviation and less than or equal to 10% percent relative standard 
deviation (222). The analytical method was therefore deemed to be acceptable in terms of 
repeatability. 
3.2.3.2 Intermediate Precision (Ruggedness) 
Intermediate precision refers to the results from intra-laboratory variations due to random 
events such as differences in experimental periods, analysts and equipment (220). In 
determining intermediate precision, data from three replicate determinations of each of 
four concentration levels covering the specified range were collected. Inter-day precision 
of the calibration standards were assessed over a one week period. 
The percent relative standard deviation obtained from three determinations over four 
different concentration levels is shown in table 3.7. 
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CON CENTRA TION MEAN PEAK STANDARD PRECISION 
(~g/ml) AREA (n=3) DEVIATION (%RSD) 
125.3 1784999 30824 1.7 
12.5 205329 12354 6.0 
6.3 99182 3831 3.9 
1.3 22370 1477 6.6 
Table 3.7 Intermediate precision with respect to four concentration levels 
The figures of merit for acceptable precision were taken as less than or equal to 10% 
relative standard deviation and less than or equal to 10% percent relative standard 
deviation (222). The analytical method was therefore deemed to be acceptable in terms of 
intermediate precision. 
3.2.3.3 Reproducibility 
Reproducibility refers to the results of collaborative studies between laboratories, and was 
not assessed. 
3.2.4 Specificity 
Specificity is the ability to measure accurately and specifically the molecule of interest in 
the presence of other components that may be expected to be present in the sample matrix. 
It is the measure of the degree of interference from such things as other active ingredients, 
excipients, impurities, and degradation products, ensuring that a peak response is due only 
to a single component; i.e., that no co-elutions exist (220). Specificity was assessed by 
analysing samples made up from serial dilutions of a 5% mfm proprietary ibuprofen-
containing gel and a 0.2 M phosphate buffer (pH 7.2) solution. The peaks obtained were 
well resolved from the solvent front and no interference was observed, indicating that the 
method was specific for ibuprofen. 
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3.2.5 Limit of Ouantitation and Limit of Detection 
The limit of detection (LOD) is defined as the lowest concentration of a molecule in a 
sample that can be detected, though not necessarily quantitated. The limit of quantitation 
(LOQ) is defined as the lowest concentration of a molecule in a sample that can be 
determined with acceptable precision and accuracy under the stated operational conditions 
of the method. Both are expressed as a concentration, with the precision and accuracy of 
the measurements also reported (220). 
There are four commonly used methods for determining LOD and LOQ reported in the 
literature (220,222,224). The method most applicable to this validation states that the LOQ 
is the lowest concentration with a percent RSD of less than 10% on multiple 
determinations (n=6 for the purposes of the study), and that the LOD is 30% of the LOQ. 
The LOQ was found to be 0.5 J..lg/ml, which had a percent RSD of less than 10%. The LOD 
was found to be 0.3 J..lg/ml, which showed a percent RSD of less than 20%. 
3.2.6 Linearity 
Linearity is the ability of the method to elicit test results that are directly proportional to 
molecule concentration within a given range. The ICH guidelines recommend that five 
concentrations spanning the concentration range to be studied be used (220). 
A calibration curve was constructed over the concentration range 0.6 - 125.3 J..lg/ml by 
linear regression of the peak areas obtained versus the concentration. Three replicate 
determinations of each of seven concentrations were used. The calibration curve was 
linear over the concentration range studied, with r2 = 0.9998. The equation of the 
regression line is y = 14197x + 9271. 
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Figure 3.1 Calibration curve 
3.2.7 Stability of the Molecule 
The molecule must remain stable in solution for the duration of the analysis and under the 
conditions of an analytical run. Ibuprofen remained stable throughout the analytical 
procedure, as selected samples from an in vitro diffusion experiment were re-analysed after 
a storage period of two months at ambient conditions and showed no statistically 
significant differences in detector response when compared to the initial analysis. 
3.2.8 Conclusion 
Validation of the analytical method established that the performance characteristics of the 
optimised method met the requirements for the intended analytical applications. The 
results obtained with this analytical method show that it is precise, accurate, sensitive, 
rapid and specific with regard to ibuprofen. It is capable of processing small volumes, is 
inexpensive and simple to perform. 
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CHAPTER FOUR 
THE IN VITRO RELEASE OF IBUPROFEN 
4.1 EXPERIMENTAL METHOD DEVELOPMENT 
4.1.1 Introduction 
In vitro approaches, such as in vitro dissolution, are standard methods used to assess the 
performance characteristics of solid oral dosage formulations. In vitro dissolution may be 
used specifically to guide formulation development, monitor formulation quality from 
batch to batch, monitor control of the formulation manufacturing process, and possibly 
predict in vivo performance. When used as a quality control procedure, in vitro dissolution 
testing can demonstrate changes in drug and/or excipient characteristics or in the 
manufacturing process. Extension of in vitro dissolution methodology to semisolid dosage 
forms would be useful for the same reasons that such methodology has proved valuable in 
the development, manufacture, and batch-to-batch quality control of solid oral dosage 
forms. Present quality control tests to assure the identity, strength, quality, purity and 
potency of the active ingredient in semisolid dosage forms may provide little or no 
information about the drug release properties of the product, stability of the product or 
effects of manufacturing and processing variables on the performance of the dosage form. 
A drug release test for topical products, analogous to a dissolution test for a solid oral dose 
form, is therefore of interest (223). 
4.1.2 In Vitro Release Testing 
In vitro release is one of several methods used to monitor performance characteristics of a 
topical dosage form. Important changes in the characteristics of a drug product or in the 
thermodynamic properties of the drug substance in the dosage form may be manifested as a 
difference in drug release. The shape and design of the in vitro diffusion cell is 
standardised by the guidelines describing the Franz and European Pharmacopoeia cell 
systems, however, other parameters such as membranes and receptor solutions have to be 
investigated individually. The characteristics of the membrane and receptor phase 
composition may influence the drug release from topical formulations. The membrane 
should be chemically inert and permeable to the drug and should not be rate limiting in the 
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release process. The receptor fluid must be able to solubilise the drug and should not alter 
the dosage form by back diffusion through the membrane. The choice of the medium 
depends on the physicochemical characteristics of the drug and the formulation (225). 
An FDA guidance document (224) recommends the following methodology for in vitro 
release studies: 
1. A static diffusion cell system as described in figure 2.2. 
2. Appropriate inert, porous, and commercially available synthetic membrane of 
appropriate size to fit the diffusion cell diameter. 
3. Appropriate receptor medium with proper justification. 
4. A minimum of six samples is recommended to determine the release rate of the 
topical formulation. 
5. About 300 mg of the semisolid preparation should be placed uniformly on the 
membrane and kept occluded to prevent solvent evaporation and compositional 
changes. This corresponds to an infinite dose condition. 
6. Multiple sampling times over an appropriate time period to generate an adequate 
release profile and to determine the drug release rate is suggested. 
7. Appropriate validated, specific, and sensitive analytical procedure, generally hp1c, 
should be used to analyse the samples and to determine the drug concentration and 
the amount of drug released. 
8. A plot of the amount of drug released per unit membrane area (J.lglcm2) versus 
square root of time should yield a straight line. The slope of the line (regression) 
represents the release rate of the product. 
9. The in vitro release test can be completely automated. 
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4.1.3 Choice of Apparatus 
The FDA guidelines were considered when choosing the apparatus to be used in the 
comparative diffusion study on proprietary ibuprofen-containing topical preparations from 
three countries and the verification of the usefulness, or otherwise, of shed snake skin as a 
biological membrane for the assessment of the permeation of ibuprofen. 
Two diffusion techniques were considered appropriate for the measurement of the amount 
of ibuprofen released from a topical formulation during in vitro testing. One was the Franz 
diffusion cell, as modified by Keshary and Chien (88,169) and the other was the European 
Pharmacopoeia diffusion cell (187). 
4.1.4 Choice of Diffusion Test Conditions 
4.1.4.1 Membrane Selection 
Three different synthetic membranes were assessed: filter, cellulose acetate and silastic 
media. The in vitro diffusion was performed in modified Franz cells (88,169) using three 
different synthetic membranes with 100 mg of 5% ibuprofen gel (Ibuleve, South Africa) in 
the donor compartment. The cells were maintained at 37°C throughout the 72 hour period. 
The receptor fluid (20% methanol/water) was analysed for ibuprofen at 1, 2,4,6, 8, 12 and 
24 hours by the hplc method described. The Franz cells were completely emptied at each 
sampling time and refilled with fresh receptor fluid. 
The choice of synthetic membrane for the in vitro comparative diffusion study on 
proprietary ibuprofen-containing topical preparations was dictated by the diffusion profiles 
(cumulative amount released vs. time) obtained as well as membrane characteristics. The 
diffusion profiles are shown in Figure 4.1. 
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Effect of synthetic membranes on the diffusion of ibuprofen 
The filter membranes investigated were Isopore Membrane Filters (Millipore, Ireland), 
with pore sizes of 0.1 /lm, 0.4 /lm and 1.2 /lm. The porous filter media appear to be most 
useful as a dividing medium or as supporting screens where the release rate of drug from 
the topical formulation is under investigation, and not the transdermal kinetics of the 
permeant. The filter medium provides no significant barrier to diffusant passage. This can 
be seen as a dose-dumping effect which occurred between 0 and 8 hours after which time 
steady state was reached. 
Generally, cellulose membranes are reported to be more permeable than biological 
membranes or aporous synthetic media (62) and are non-discriminatory to the 
characteristics of the diffusant molecule. This was found to be true as the diffusion profile 
of ibuprofen through the cellulose acetate membrane (Bel-Art Products, New Jersey, USA) 
mimicked that of the filter membranes and provided no significant barrier to the passage of 
ibuprofen through the membrane. 
Silicone membrane is considered the most useful of the synthetic media for use in diffusion 
cell systems. Its relatively inert, lipophilic nature makes it an ideal environment for 
partitioning and permeation of drugs while its aporosity provides some rate-limiting 
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function to this process. The diffusion profile of ibuprofen through the Silatos Silicone 
Sheeting (Atos Medical, Horby, Sweden) indicated that the membrane exhibited a rate-
limiting function. The Silatos Silicone Sheeting was deemed to be an appropriate inert, 
porous, and commercially available synthetic silastic membrane of appropriate size to fit 
the diffusion cell diameter and was therefore used in the comparative diffusion study on 
proprietary ibuprofen-containing topical preparations from three countries. 
Shed snake skin from four species of snake was used for the verification of the usefulness, 
or otherwise, of shed snake skin as a biological membrane for the assessment of the in 
vitro permeation of ibuprofen. These were Naja nivea (Cape cobra), Naja haje haje 
(Egyptian cobra), Naja melanoleuca (forest cobra), and Python sebae natalensis (African 
rock python). The shed snake skins were cut to an appropriate size to fit the diffusion cell 
diameter. 
4.1.4.2 Receptor Medium Selection and Preparation 
Ibuprofen is practically insoluble in water, but is readily soluble in most organic solvents 
and is soluble in aqueous solutions of alkali hydroxides and carbonates (1-3). Based on the 
solubility of ibuprofen, five solutions were chosen as possible receptor media for 
investigation. The five solutions are listed in table 4.1. 
20% Methanol / Water 
0.2M Phosphate Buffer Solution at pH 7.2 
0.5 % Sodium Lauryl Sulphate / Water 
6% Polyethyleneglycol / Water 
0.1 % Sodium Carbonate / Water 
Table 4.1 Receptor media investigated 
The in vitro diffusion was performed in modified Franz cells (88,169) using Silatos 
Silicone Sheeting membrane with 100 mg of 5% ibuprofen gel (Ibuleve, South Africa) in 
the donor compartment. The cells were maintained at 37°C throughout the 72 hour period. 
The receptor fluid was analysed for ibuprofen at 2, 4, 8, 24, 48 and 72 hours by the hplc 
method described. The Franz cells were completely emptied at each sampling time and 
67 
refilled with fresh receptor fluid. The effect of the receptor medium on the diffusion 
profile of ibuprofen is shown in figure 4.2. 
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Effect of receptor medium on the diffusion profile of ibuprofen 
The alcoholic solution produced excess bubble formation on the undersurface of the 
membrane which reduced the surface area available for diffusion and was subsequently 
rejected. The 0.2M phosphate buffer solution at pH 7.2 proved to be the most efficient of 
the aqueous receptor solutions over 0.5% sodium lauryl sulphate/water, 0.1 % sodium 
carbonate/water and 6% polyethyleneglycol. The phosphate buffer solution was therefore 
chosen for subsequent determinations since there was little bubble formation beneath the 
membrane in the Franz cell and it showed the lowest tendency for evaporation. This is in 
accordance with the dissolution medium as specified by the USP for ibuprofen (3). With 
regard to the European Pharmacopoeia dissolution cells, bubble formation and evaporation 
are not problematic as neither of these factors are present when the apparatus is assembled. 
The receptor medium was prepared as follows: 61.5 ml of 85% orthophosphoric acid 
(Saarchem-Holpro Analytic, Pty., Ltd., Krugersdorp, South Africa) was pipetted into a 5 1 
volumetric flask and made up to volume with hplc grade water. The pH was then adjusted 
to 7.2 using sodium hydroxide pellets (Riedel-deHaen, Germany). A Crison pH meter 
(Crison, LASEC, South Africa) was used for pH measurements. The solution was filtered 
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through a 0.44 f.lm filter (Millipore, Maryland, USA) and degassed under vacuum before 
use. 
4.1.4.3 Temperature of the Receptor Medium 
The in vitro diffusion experiment to determine the optimum temperature of the receptor 
medium was performed in modified Franz cells (88,169) using Silatos Silicone Sheeting 
membrane with 100 mg of 5% ibuprofen gel (Ibuleve, South Africa) in the donor 
compartment. The cells were maintained at 37°C (n=5) and at 32°C (n=5) throughout the 
72 hour period. The receptor fluid (0.2M phosphate buffer at pH 7.2) was analysed for 
ibuprofen at 2, 4, 8, 24, 48 and 72 hours by the hplc method described. The Franz cells 
were completely emptied at each sampling time and refilled with fresh receptor fluid. 
2000,---------------------------------, 
1800 
N~ 
E 1600 
~ 
OJ 
61400 
"0 
Q) 
~ 1200 
Q) 
a:; 
-E 1000 
::l 
o 
E 800 
CIl 
.~ iii 600 
"5 § 400 
() 
200 
o 
Figure 4.3 
o 1 0 20 30 40 50 60 70 80 
Time (hours) 
Diffusion medium at 32°C 
Diffusion medium at 37°C 
The effect of temperature on the diffusion profile of ibuprofen 
As can be seen in figure 4.3, no significant difference in the diffusion profile of ibuprofen 
is apparent due to temperature differences of the diffusion medium, therefore 32°C was 
chosen as the temperature at which the diffusion experiments were to be performed as less 
evaporation of the receptor medium occurred at the lower temperature, and possibly less 
degradation of the active. 
69 
4.1.4.4 Number of Samples and Sampling Time 
A minimum of six samples is recommended to determine the release rate (diffusion 
profile) of a topical formulation (224). The recommended number of six samples is based 
on the design of the diffusion cell apparatus which commonly has six sample stations. The 
design of the diffusion cell follows the imperial numerical system which has been replaced 
by the metric system. In accordance with the metric system five samples taken at each 
sampling time were deemed to be sufficient to give a diffusion profile from which the 
kinetics of the diffusion process could be calculated. 
Samples of receptor fluid were taken at 2, 4, 8, 24, 48 and 72 hours. These multiple 
sampling times were chosen over an appropriate time period to generate an adequate 
diffusion profile and to determine the drug release rate. The Franz cells were completely 
emptied at each sampling time and refilled with fresh receptor fluid. Aliquots of 2 ml were 
taken from the European Pharmacopoeia cells at each sampling time before anal ysis using 
the hplc method described in chapter 3. The total percentage of receptor fluid removed for 
sample analysis was 1.2% which was deemed to be too small a volume to disrupt sink 
conditions. 
4.1.4.5 Sample Applications 
The effect of the mass of the sample application was investigated in modified Franz cells 
(88,169) using Silatos Silicone Sheeting membrane with 50 mg (n=3), 100 mg (n=5) and 
200 mg (n=2) of 5% ibuprofen gel (Thuleve, South Africa) in the donor compartment. The 
cells were maintained at 32°C throughout the 72 hour period. The receptor fluid (0.2M 
phosphate buffer at pH 7.2) was analysed for ibuprofen at 2, 4, 8, 24, 48 and 72 hours by 
the hplc method described. The Franz cells were completely emptied at each sampling 
time and refilled with fresh receptor fluid. Figure 4.4 shows the effect of mass on the 
diffusion profile of ibuprofen. 
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Effect of mass on the diffusion profile of ibuprofen 
All three diffusion profiles are significantly different. 100 mg was chosen as the sample 
application over 50 mg as the cumulative amount of ibuprofen released is greater, thus 
giving a better diffusion profile. 200 mg was deemed to be excessive both in economic 
terms as well as the possibility that a large sample application may result in saturation 
kinetics. 
Approximately 100 mg of the proprietary ibuprofen-containing topical formulation (5% 
mlm) was uniformly placed on the membrane and kept occluded, in the case of the Franz 
cell, to prevent solvent evaporation and compositional changes. The amount of topical 
formulation per unit membrane area available to the diffusant in the Franz cell donor 
chamber was calculated to be 60.63 mg/cm2• From this figure the corresponding sample 
application was calculated for the European Pharmacopoeia cell. Approximately 500 mg 
of the proprietary ibuprofen-containing topical formulation (5% mlm) was uniformly 
placed on the membrane, ensuring no air bubbles were present between the surface of the 
formulation and the membrane. As the mass of topical formulation to the unit of surface 
area available to the diffusant was identical for both the Franz and the European 
Pharmacopoeia cells, direct comparisons of the diffusion profiles was possible. 
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4.1.5 Dissolution Profile Comparison 
Dissolution profile similarity depends on the similarity between the profiles at each time 
point and the similarity between the overall profiles. The similarity between overall 
profiles is particularly important for topical dosage forms. When comparing dissolution 
profiles it is important to ensure that the test conditions are identical (219). The diffusion 
profiles of ibuprofen using four different species of shed snake skin as a biological 
membrane and the diffusion profiles of proprietary ibuprofen-containing topical 
preparations from three countries were compared. 
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4.2 ELECTRON MICROSCOPY 
4.2.1 Introduction 
An electron microscope is an instrument in which an electron beam is used to create an 
enlarged image of a subject under investigation. Electron microscopes allow the 
observation of much finer detail than any other form of microscope which uses light in the 
creation of enlarged images. The two main types of electron microscopes are the 
transmission electron microscope (TEM) and the scanning electron microscope (SEM). A 
scanning electron microscope (lEOL JSM 840) was used to determine the integrity, 
surface morphology and thickness of the snake skins investigated in this study. 
4.2.2 Scanning Electron Microscopy 
An electron beam is focussed by electro magnetic lenses on to the surface of a specimen. 
Scanning coils are used to make the beam scan in a raster fashion across the specimen (up 
to 3000 scans per rectangular field of view). The interaction between the incident electron 
beam and the specimen causes the liberation of secondary electrons, and other 
electromagnetic radiation such as X-rays, back-scattered electrons and light. The 
secondary electrons are attracted by a small positively-charged grid to a detector where the 
secondary electrons emitted from any given point on the raster create a signal which is 
amplified and used to modulate a beam on a cathode ray tube which is scanning in 
synchrony with the beam in the SEM column. This creates a pattern of light and dark areas 
corresponding to the emission of secondary electrons from the specimen from the same 
area, as registered by the detector. As the number of electrons produced at any given point 
can be related directly to the topography of the specimen with respect to the detector, the 
pattern created on the viewing screen represents the surface topography of the specimen. 
Magnification is created by setting the scanning coils to scan progressively smaller 
rectangular areas of the specimen. The images are recorded on conventional film by 
photography of the scan on a second cathode ray tube. 
The elemental composition of the surface of the specimen will also affect the electron 
emission. While this is used as an analytical tool in some cases, for surface morphology 
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studies such as those conducted on the snake skins the specimen surface is coated with a 
thin layer of gold and thus has a uniform elemental composition (243). 
4.2.3 Specimen Preparation for Scanning Electron Microscopy 
The environment in the specimen chamber of the scanning electron microscope (vacuum, 
heat generated by the electron beam) demands stabilisation of the biological specimens to 
ensure that images obtained by the SEM are reproductions of the structure of the specimen 
in its natural state. There are both physical and chemical ways of achieving this objective. 
4.2.3.1 Chemical Methods 
Chemical-based methods for preparing biological specimens for SEM involve fixation, 
dehydration, drying and metal coating. 
Fixation is a procedure involving the use of chemicals to counteract normal post-mortem 
enzymatic action and cross-link the chemical constituents of the living material into a form 
which will withstand the effects of the alien environment within the SEM specimen 
chamber. 
Dehydration involves the use of a series of ascending concentrations of a dehydrating 
agent (ethanol, acetone) to remove water from the specimen. 
Drying of the specimen is a crucial step in the process in that it should not result in any 
distortion of the shape, size and form but leave it in a state which reproduces its shape, size 
and form in its natural state. This step is necessary, however, as free water cannot be 
present in the specimen because of the vacuum environment in the SEM specimen 
chamber. Some degree of shrinkage is almost inevitable but procedures such as critical 
point drying (CPD) and air-drying from low vapour pressure solvents (HMDS) provide 
good preservation of structure. The choice of procedure depends upon available 
technology and the specimen under investigation. 
Metal coating is applied before the dried biological specimens can be examined 
successfully in the SEM. This coating, which is usually a thin «100nm) layer of gold or 
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gold alloy deposited on the specimen surface, either by sputter-coating or vacuum 
evaporation, has four functions: 
1. To increase the level of secondary electron emission from the surface of the specimen 
and thus optimise the brightness and contrast of the image and the achievable 
resolution of fine detail. 
2. To eliminate the effects of atomic number contrast in the surface layers of the 
specimen. 
3. To prevent the build-up of electrical charges in the specimen by allowing these charges 
to discharge to earth. 
4. To ensure that secondary electron emission is confined to the surface layers of the 
specimen and thus avoid confusion caused by emission from deeper layers within the 
specimen. 
Fixation and dehydration were unnecessary steps in the preparation of the shed snake 
skins. The specimens are essentially non-living structures and do not require chemicals to 
counteract post-mortem enzymatic action and cross-link the chemical constituents of the 
living material nor do they require dehydration as the shed snake skins were examined in 
their naturally dehydrated state. The specimens were therefore cut with scissors, dried and 
sputter-coated with a thin layer of gold. 
4.2.3.2 Physical Methods 
These are based on stabilising the specimen by freezing the free water within it. It is most 
important when using such methods to ensure that the freezing process and the formation 
of ice-crystals dies not cause distortion of the specimen. 
Once frozen the specimens can be further prepared for SEM observation by direct 
observation in frozen state by cryoSEM or after freeze drying. Metal coating is still 
required for optimal results both for cryoSEM and for observation of freeze-dried 
specimens by conventional SEM. Freeze-drying involves the rapid freezing of a specimen, 
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with or without cryo-protection, transfer of the frozen specimen to a vacuum followed by 
drying through sublimation of ice from the specimen (243). 
4.2.4 Scanning Electron Microscopy Instrumentation and Conditions 
A scanning IEOL ISM 840 microscope was used at the following settings: 
Acceleration voltage 12.0 kV 
Optical aperture 3 
Probe current 
Working distance 
10 amp 
39mm 
The images were recorded using a Mamiya roll film adaptor camera on conventional Agfa 
Agfapan (APX 1001120) film by photography of the scan on a second cathode ray tube. 
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4.3 THE DIFFUSION PROFILES OF PROPRIETARY IBUPROFEN· 
CONTAINING TOPICAL PREPARATIONS FROM THREE COUNTRIES 
4.3.1 Introduction 
One of the factors that requires consideration during the development of topical 
formulations is the climatic conditions under which the medicament is to be utilised. 
Preparations formulated for use in temperate climates may not be suitable for use in 
tropical or sub-tropical climates and vice versa (226). The vehicle may greatly influence 
the release of the drug. This study investigated the diffusion profiles obtained from 
proprietary ibuprofen formulations purchased in three countries, namely South Africa 
(SA), France (FR) and the United Kingdom (UK). South Africa has a sub-tropical climate, 
while France and the United Kingdom have a temperate climate. The formulations used in 
this study are listed in table 4.2. The composition in terms of the ingredients in each 
formulation, made available by the manufacturer, is listed in appendix II. 
PRERARATION (5% mfm) PURCHASED MANUFACTURED 
Deep Relief Gel South Africa United Kingdom 
Ibuleve Gel South Africa South Africa 
Deep Relief Gel United Kingdom United Kingdom 
Ibuleve Gel United Kingdom United Kingdom 
Ibuleve Mousse United Kingdom United Kingdom 
Nurofen Gel United Kingdom United Kingdom 
Proflex Cream United Kingdom United Kingdom 
Radian B Gel United Kingdom United Kingdom 
Ralgex Gel United Kingdom United Kingdom 
Cliptol Gel France France 
Dolgit Cream France France 
Ibutop Gel France France 
Intralgis Gel France France 
Syntofene Gel France France 
Tiburon Gel France France 
Table 4.2 Proprietary ibuprofen-containing topical formulations 
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The French and UK preparations were transported to South Africa on a commercial flight 
in the hand luggage of the purchaser thereby avoiding possible adverse effects of 
temperature extremes during transportation. Each of the different products from the three 
countries was assayed using the experimental and analytical methodology described in 
chapter 3 and section 4.1. 
Numerous authors have stated that commercially available products were used in studies 
involving topical ibuprofen, but have not reported the tradenames. In several cases where 
proprietary products were used, the name or names of only the principal products are 
presented. Inter-laboratory comparisons are unreliable unless tradenames or formulae of 
vehicles are reported. Authors should therefore, where possible, report the tradenames or 
formulae of the formulations used (226). Since many tradenames are the same in different 
countries, the country of manufacture should also be reported. 
4.3.2 Comparisons of Ibuprofen Creams, Gels and Mousses 
The in vitro permeation of ibuprofen from commercially available formulations through a 
silastic silicone membrane was monitored over a period of 72 hours. The experimental 
methodology as outlined in section 4.1 was adopted. 
Individual and mean apparent release constants were obtained by linear regression analysis 
of plots of cumulative amount of released drug Olg/cm2) versus square root of time (h1!2). 
This relationship between drug release and square root of time was previously shown to be 
valid for topical formulations with either fully dissolved or suspended active ingredients 
(227-233). The "square root of time law" can be applied to ibuprofen release from the 
various topical formulations because firstly, only a single drug diffuses out of the dosage 
forms with a percentage of drug release less than 30% after a 20 hour period. Secondly, 
sink conditions are ensured by the large receptor volume of the European Pharmacopoeia 
diffusion cell and the replacement of receptor fluid at each sampling time when using the 
Franz diffusion cell. 
By linear regression of the curves representing cumulative ibuprofen release per centimetre 
squared versus square root of time, an apparent release constant corresponding to the 
measured slope was obtained. The lag time, defined by the intercept on the square root of 
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time axis was also used to compare drug release from different formulations. This lag time 
corresponds to the time it takes for drug molecules to be released from the dosage form and 
to diffuse across the synthetic membrane, the latter not being rate limiting. 
The diffusion profiles obtained for the ibuprofen formulations studied using both the Franz 
and European Pharmacopoeia diffusion cells are shown in figure 4.5 and figure 4.6. 
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Figure 4.5 The diffusion profiles obtained for ibuprofen formulations using the Franz 
diffusion cell 
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Figure 4.6 The diffusion profiles obtained for ibuprofen formulations using the 
European Pharmacopoeia diffusion cells 
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The diffusion profiles obtained for the ibuprofen formulations using both the Franz and 
European Pharmacopoeia diffusion cells have been divided into three groups based on the 
range of the respective apparent release constants (f.lg/cm2/h1l\ This enabled the data to 
be presented in clear graphic images, thus facilitating interpretation. 
4.3.2.1 Results Obtained Using the Franz Diffusion Apparatus 
The diffusion profiles using the Franz diffusion cell apparatus are depicted as follows: 
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Figure 4.9 Ibuprofen diffusion profiles (range 28-36 Ilglcm2/hll2) 
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The release constants, lag times and correlation coefficients (r2) for ibuprofen-containing 
topical formulations using the Franz diffusion cell apparatus are shown in table 4.3. 
FORMULATION APPARENT RELEASE LAG TIME r2 
CONSTANT (J1g/cm2/h1l2) (hl/2) 
Dolgit Cream (FR) 318.03 0.46 0.9891 
Proflex Cream (UK) 312.91 0.57 0.9803 
Ralgex Gel (UK) 296.37 0.41 0.9641 
Ibutop Gel (FR) 286.09 0.44 0.9603 
Ibuleve Gel (UK) 241.87 0.67 0.9794 
Deep Relief Gel (SA) 176.25 0.37 0.9783 
Ibuleve Gel (SA) 176.0 0.67 0.9752 
Nurofen Gel (UK) 171.93 0.45 0.9937 
Deep Relief Gel (UK) 155.81 0.64 0.9627 
Cliptol Gel (FR) 145.02 0.37 0.9842 
Ibuleve Mousse (UK) 114.46 0.25 0.9931 
Tiburon Gel (FR) 35.86 0.73 0.9515 
Intralgis Gel (FR) 29.86 2.5 0.8295 
Radian B Gel (UK) 29.21 0.44 0.9808 
Syntofene Gel (FR) 28.15 0.99 0.9348 
Table 4.3 The release constants, lag times and r2 values for ibuprofen-containing 
topical formulations, using the Franz diffusion cell apparatus 
The rank order of drug permeation from the formulations (J..lglcm2) at 72 hours is Dolgit 
Cream (FR), Ralgex Gel (UK), Proflex Cream (UK), Ibutop Gel (FR), Ibuleve Gel (UK), 
Deep Relief Gel (SA), Ibuleve Gel (SA), Nurofen Gel (UK), Cliptol Gel (FR), Deep Relief 
Gel (UK), Ibuleve Mousse (UK), Tiburon Gel (FR), Intralgis Gel (FR), Syntofene Gel 
(FR) and Radian B Gel (UK). There is a significant statistical difference at a 95% 
confidence interval between the formulations of groups one, two and three. 
The gel formulations in the first group have the highest initial release rates (Ralgex 218 ± 9 
J..lg/cm2/h and Ibutop 217 ± 19 J..lg/cm2/h) which steadily decrease over the sampling time 
period to a release rate that is less than that of the two cream formulations. Steady state is 
gradually approached at 72 hours. The cream formulations exhibit the same steady 
decrease in release rates (initial release rates: Dolgit 97 ± 14 J..lg/cm2/h and 
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Proflex 82 ± 11 J..lglcm2/h). The gel and mousse fonnulations in the second group show a 
similar decrease from an average initial release rate of 77 J..lg/cm2/h. The individual release 
rates are shown in appendix III. The third group of gel fonnulations have much lower 
initial release rates and reach a relatively low constant rate of delivery of approximately 2 
J..lg/cm2/h after 12 hours. 
When the cumulative amount of drug released per square centimetre was plotted against 
the square root of time, a linear relationship was obtained for the cream, mousse and gel 
formulations from group one and two (r2>0.96), showing that the release of ibuprofen from 
the fonnulations was well described by the Higuchi model, where the rate controlling step 
is the process of diffusion through the gel matrix. This relationship exists for fonnulations 
in which the drug is fully dissolved and in which the drug is present as a suspension. 
Hence, the membrane has no significant effects and the properties of the fonnulation 
control the release of the drug (229). The gel fonnulations in group three, excluding 
Radian B gel which has a correlation coefficient greater than 0.98, do not confonn to the 
same linear relationship. The exception of Radian B gel may be due to the fact that 
although all four of the fonnulations in group three contain the same ingredients, the 
percentages of the ingredients in Radian B gel may differ from those of the other three 
gels. 
The two cream fonnulations have the greatest apparent release constants. Dolgit cream 
(318 J..lg/cm2 /h 112) has a slightly greater apparent release constant than Proflex cream 
(313 J..lg/cm2/h112). The apparent release constants of the gel fonnulations ranged from 
28 - 242 J..lg/cm2 /h1l2. The mousse fonnulation has an apparent release constant of 
114 J..lg/cm2 /h1l2, which falls roughly mid-way in the gel range. The fonnulations are 
listed in table 4.4 in decreasing order of the apparent release constants. 
The observed lag times were short, ranging from 0.25 - 0.67 h1l2 for the cream mousse and 
gel fonnulations in groups one and two. Longer lag times over a greater range 
(0.44 - 2.5 h1l2) were observed for group three. The longer lag time values indicate that 
ibuprofen is preferentially retained by the fonnulation base. 
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4.3.2.2 Results Obtained Using the European Pharmacopoeia Diffusion Apparatus 
The diffusion profiles using the European Pharmacopoeia diffusion cell apparatus are 
depicted as follows: 
RANGE (J.LgIcm2 1b1l2) FIGURE 
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Figure 4.10 Ibuprofen diffusion profiles (range 283-369 J..lglcm2/h1l2) 
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The release constants, lag times and r2 values for ibuprofen-containing topical 
formulations, using the European Pharmacopoeia diffusion cell apparatus, are shown in 
table 4.4. 
FORMULATION APPARENT RELEASE LAG TIME rZ 
CONSTANT (J..Lg/cm2 /h1l2) (hI/2) 
Dolgit Cream (FR) 369.30 0.19 0.9835 
Proflex Cream (UK) 363.28 0.09 0.9938 
Ralgex Gel (UK) 298.65 0.72 0.9562 
Ibutop Gel (FR) 296.29 1.03 0.9353 
Ibuleve Gel (UK) 283.04 0.86 0.9755 
Ibuleve Gel (SA) 242.39 0.14 0.9985 
Cliptol Gel (FR) 239.90 0.98 0.9660 
Nurofen Gel (UK) 221.49 0.70 0.9765 
Deep Relief Gel (UK) 208.39 0.93 0.9717 
Ibuleve Mousse (UK) 188.20 0.33 0.9903 
Deep Relief Gel (SA) 180.60 0.64 0.9843 
Intralgis (FR) 80.06 1.65 0.9184 
Radian B Gel (UK) 55.27 0.30 0.9828 
Tiburon Gel (FR) 55.04 2.64 0.8268 
Syntofene Gel (FR) 55.02 1.89 0.9041 
Table 4.4 The release constants, lag times and r2 values for ibuprofen-containing 
topical formulations, using the European Pharmacopoeia diffusion cell 
apparatus 
The rank order of drug permeation from the formulations (Jlglcm2) at 72 hours is Dolgit 
Cream (FR), Proflex Cream (UK), Ibuleve Gel (UK), Ibutop Gel (FR), Ralgex Gel (UK), 
Cliptol Gel (FR), Ibuleve Gel (SA), Nurofen Gel (UK), Deep Relief Gel (UK), Ibuleve 
Mousse (UK), Deep Relief Gel (SA), Intralgis Gel (FR), Tiburon Gel (FR), Syntofene Gel 
(FR) and Radian B Gel (UK). There is a significant statistical difference at a 95% 
confidence interval between the formulations of groups one, two and three. 
The gel formulations in the first group have the highest initial release rates (Ralgex 245 ± 
120 Jlglcm2fh, Ibutop 347 ± 26 Jlg/cm2fh and Ibuleve UK 283 ± 141 Jlg/cm2fh) which 
steadily decrease over the sampling time period to a release rate that is less than that of the 
two cream formulations. Steady state is gradually approached at 72 hours. The cream 
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formulations exhibited the same steady decrease in release rates (initial release rates: 
Dolgit 236 ± 116 J1,glcm2/h and Proflex 193 ± 95 J1,g/cm2/h). The gel and mousse 
formulations in the second group show a similar decrease from an average initial release 
rate of 195 J1,g/cm2/h. The individual release rates are shown in appendix ill. The third 
group of gel formulations have very much lower initial release rates and reach a relatively 
low constant rate of delivery of approximately 4 J1,glcm2/h after 12 hours. 
When the cumulative amount of drug released per square centimetre was plotted against 
the square root of time, a linear relationship was obtained for the cream, mousse and gel 
formulations of group one and two (r2>0.93), showing that the release of ibuprofen from 
the formulations was well described by the Higuchi model, where the rate controlling step 
is the process of diffusion through the gel matrix. This relationship exists for formulations 
in which the drug is fully dissolved and in which the drug is present as a suspension. 
Hence, the membrane has no significant effects and the properties of the formulation 
control the release of the drug (229). The gel formulations in group three, excluding 
Radian B gel which has a correlation coefficient greater than 0.98, do not conform to the 
same linear relationship. The exception of Radian B gel may be due to its percentage 
composition. 
The two cream formulations have the greatest apparent release constants. Dolgit cream 
(369 J1,g/cm2/h1l2) has a slightly greater apparent release constant than Proflex cream (363 
J1,glcm2 /h 112). The apparent release constants of the gel formulations ranged from 55 - 299 
J1,glcm2 /h 1l2• The mousse formulation has an apparent release constant of 188 J1,glcm2 /h 1l2, 
which falls roughly mid-way in the gel range. The formulations are listed in table 4.4 in 
decreasing order of the apparent release constants. 
The observed lag times were found to be longer than those found using the Franz diffusion 
cells and ranged from 0.09 - 1.03 h1!2 for the cream, mousse and gel formulations in 
groups one and two. Longer lag times over a greater range (0.3 - 2.64 h1!2) were observed 
for group three. The longer lag time values indicate that ibuprofen is preferentially 
retained by the formulation base. 
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4.3.3 Discussion 
Drug penetration is dependent upon the influence of the vehicle on the thermodynamic 
activity of the active ingredient. Ibuprofen is a poorly water-soluble drug, hence its release 
is favoured from hydrophilic bases such as the gels and the oil-in-water formulations 
which are poor solvents for the drug. Consequently, there are fewer drug-vehicle 
interactions leading to improved partitioning of the drug into the membrane. 
Each formulation within the three groups showed similar results for correlation 
coefficients, apparent release constants, lag times and release rates. This may be explained 
by examining the compositions of the formulations within the three separate groups 
(Appendix m. Group one consisted of two cream formulations both containing propylene 
glycol and a hydrophilic non-ionic surfactant and two gel formulations with identical 
compositions to each another. In addition to the two creams, the gel formulations of group 
two contained propylene glycol. Group three consisted of four gel formulations which had 
identical formulations and were the only formulations that contained sodium hydroxide. 
The delivery rates and apparent release constants obtained using both the Franz and 
European Pharmacopoeia diffusion apparatus can be explained by examining Fick's law of 
diffusion. The flux is proportional to the partition coefficient, the diffusion coefficient and 
the donor concentration and inversely proportional to the thickness of the membrane. In 
this experiment the intrinsic diffusion coefficient, the membrane thickness and the donor 
concentration were constant. Hence, in the absence of physical mechanisms, the rate of 
diffusion will be dictated by the partition coefficient between the donor formulation and 
the membrane. 
Ibuprofen is poorly water soluble and therefore has a low affinity for the aqueous gel and 
mousse formulations. It will therefore partition into the less hydrophilic environment of 
the silicone membrane, hence the relatively short lag times and high flux rates observed as 
these processes are concentration gradient dependent. 
The cream formulations and the two gel formulations from the first group (Ralgex and 
Ibutop) appear to present an ideal combination of solubility and physical diffusivity 
through the vehicle, yielding high ibuprofen release rates and apparent release constants. 
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A trend was observed between the cream and gel formulations when both the Franz and 
European Pharmacopoeia diffusion cells were used. The gel formulations gave a 
significantly greater initial release rate than the cream formulations and an overlap of 
ibuprofen release occurred at 48 hours, after which the release rate from the gel 
formulations decreased while the release rate from the cream formulations remained 
constant and a significant difference was once again observed between the gel and cream 
formulations. The cream is a lipophilic/hydrophilic mixture from which ibuprofen appears 
to partition readily into the silicone matrix. Relatively facile diffusion through this vehicle 
of moderate viscosity appears to allow replenishment of the drug depletion layer as 
ibuprofen is removed from the vehicle/membrane interface to a greater extent than that 
which occurs in the gel formulations. Hence the observed high flux rate and only gradual 
decline in diffusion rate after 72 hours. 
4.3.3.1 Formulation Factors 
A number of formulation factors have been considered in an attempt to explain the results 
obtained for both the Franz and European Pharmacopoeia diffusion cells. 
4.3.3.1.1 Propylene Glycol 
The formulations represented by group two consist of one mousse formulation, Ibuleve 
Mousse, and seven gel formulations, Ibuleve Gel (UK), Deep Relief Gel (SA), Ibuleve Gel 
(SA), Nurofen Gel (UK), Deep Relief Gel (UK) and Cliptol Gel (FR). The diffusion 
profiles vary greatly within this group and may be explained by the fact that all these 
formulations contain propylene glycol. No gel formulation in group one or three contains 
propylene glycol. The percentage mass/mass was not indicated for any ingredient, other 
than ibuprofen, in the formulations. Propylene glycol is classified as a humectant. The use 
of this substance brings about hydration and hydrophilisation of the membrane, thus 
facilitating the absorption of ibuprofen. Propylene glycol is also a penetration enhancer, 
which causes increased penetration of ibuprofen through the membrane by making it more 
permeable to the drug (41). 
An investigation into the vehicle-skin partition coefficients and solubilities of ibuprofen in 
a series of aqueous propylene glycol systems with different cosolvent compositions has 
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determined that the flux data show essentially a steady state flux which increases 
progressively with propylene glycol concentration. The permeability constant, however, 
peaks at about 20% propylene glycol where the efficiency of drug delivery into the 
membrane from the saturated solution appears to be maximal. The results suggest that the 
vehicle may be capable of modifying the partition properties of the membrane. At 
concentrations of 20-30% propylene glycol there appears to be a maximum partition 
coefficient, probably due to penetration of propylene glycol and an enhanced solubility of 
ibuprofen in the membrane (217,234). The various release profiles obtained for the 
formulations investigated may therefore be explained by assuming that the formulations 
differ mainly with respect to the percentage of propylene glycol in each. 
The action of propylene glycol as a potential penetration enhancer has been questioned. 
Several authors have reported that its action is based on its cosolvent effect (235). In this 
case, drug penetration is thermodynamically controlled. Only limited data demonstrate an 
enhancer effect in which drug penetration increases with increasing propylene glycol 
content of the formulation. This promoting effect is related mainly to the solvent drag 
effect of propylene glycol (236,237). 
4.3.3.1.2 EthanollIsopropanol 
All gel formulations contained either ethanol or isopropanol in unknown concentrations. 
The release profiles of the three groups may be explained by examining the action of 
alcohol on the system being investigated. Alcohol is classified as a humectant. The use of 
this substance produces varying degrees of hydration and hydrophilisation of the 
membrane, thus facilitating the absorption of ibuprofen (41). Different percentages of 
alcohol will therefore result in different diffusion profiles. 
4.3.3.1.3 Purified Water 
All formulations contained purified water. Addition of purified water to a formulation in 
which ibuprofen is less soluble increases the thermodynamic activity with consequent 
increase of the membrane penetration rate. When the percentage of water is high, which 
may be the case in the formulations with the greatest apparent release constants and release 
rates and the shortest lag times, more of the drug precipitates causing a substantial decrease 
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of solute concentration. However, the further increase in escaping tendency produces more 
rapid penetration and the undissolved drug provides a reservoir ensuring solution 
saturation with the permeant throughout the experiment (238). 
4.3.3.1.4 Sodium Hydroxide 
The third group of gel formulations contained sodium hydroxide which is a powerful base 
and is used to adjust the pH of formulations. The results obtained from this group may be 
explained by the specific interactions which can occur between ibuprofen and sodium 
hydroxide which may first decrease the activity of the drug by salt formation and even 
precipitate the drug as sparingly soluble complexes or salts (239). Another possible 
explanation may be that a certain percentage of the sodium hydroxide diffuses through the 
silastic membrane and into the receptor fluid where it may change the pH of the solution. 
The higher pH of the receptor fluid may therefore present a non-ideal environment to the 
diffusion of ibuprofen from the formulation. 
4.3.3.1.5 Surfactant 
The cream formulations contained an hydrophilic non-ionic surfactant (polyoxyethylene 
esters). Penetration through a membrane can be modified by surfactants. Interaction with 
the permeant may also occur, therefore a surfactant can either increase, decrease or have no 
effect on membrane absorption (238). Investigations into the action of hydrophilic non-
ionic surfactants have found that gels containing a polyoxyethylene fatty acid ester 
exhibited a higher release rate and significantly decreased lag time as compared to control 
gels (174). 
4.3.3.1.6 Effect of pH 
Promotion of penetration is also brought about by the pH of the formulation which was 
not assessed in this study. The pKa of ibuprofen is 4.6 and in a gel at a pH of 5.0, about 
40% of the ibuprofen is present in its neutral, undissociated form. This neutral form is 
better able to pass through the lipophilic silicone polymer into the receptor medium, where 
the pH of 7.2 causes a shift to about 99.9% dissociated ibuprofen (41). 
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4.3.3.2 Transport Factors 
The Deep Relief Gel formulation available in South Africa is imported from Britain. The 
apparent release constant as well as the release rate of Deep Relief Gel (SA) is 
significantly less at a 95% confidence level than Deep Relief Gel (UK) assessed using both 
the Franz and European Pharmacopoeia diffusion cell apparatus. One possible reason for 
this may be that the gel was formulated for use in a temperate climate and the vehicle may 
not have been a good releasing medium in a subtropical climate, or that the wide 
temperature ranges that may have been encountered during importation may have altered 
the release characteristics of the vehicle. 
This formulation would have been transported to South Africa by sea or air. It has been 
found that the temperatures in the cargo hold of a ship have been found to vary from 
I-32°C (240,241) during the cool season (June/July from South Africa to Britain and 
December/January from Britain to Hong Kong) and may be considerably hotter during the 
equatorial summers. Temperatures in the cargo hold of an aircraft may be below O°C, 
depending on the cruising altitude of the aircraft and the duration of the flight (242). The 
ideal vehicle should therefore be able to withstand storage over a temperature range of 
5-30°C. 
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4.3.4 Comparison of Diffusion cells 
The diffusion profiles obtained for each formulation, utilising the Franz and European 
Pharmacopoeia diffusion cells, are compared here in an attempt to demonstrate an 
appropriate diffusion technique for the measurement of the amount of ibuprofen released 
from a topical formulation during in vitro testing. The diffusion profiles obtained for the 
ibuprofen formulations have once again been divided into three groups based on the range 
of the respective apparent release constants in order to report the results in a consistent 
format. 
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Figyre 4.13 Ibuprofen diffusion profiles (range 286-369 Jlg/cm2/h1l2) 
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Figure 4.14 Ibuprofen diffusion profiles (range 115-283 J.lg/crn2/h1l2) 
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Figure 4.15 Ibuprofen diffusion profiles (range 28-80 Ilg/cm2 thII2) 
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4.3.4.1 Discussion 
A statistically significant difference, at a 95% confidence interval, was seen between the 
diffusion profiles obtained using the Franz and the European Pharmacopoeia diffusion 
cells for all formulations assessed with the exception of Ralgex Gel. The percentage 
standard deviation using the Franz diffusion cells was greater than the European 
Pharmacopoeia diffusion cells with the exception of Ibuleve Mousse. This deviation may 
be a result of the relatively lower viscosity of the mousse which resulted in the formation 
of air bubbles on the surface of the membrane in contact with the formulation when the 
cells were initially set up. It is therefore possible that an erratic release profile resulted as 
the diffusional area of membrane was not uniform in all five of the sample cells. The 
standard deviation of the cumulative amount of ibuprofen released per centimetre squared 
was generally greater using the Franz diffusion cells. In all cases the use of the European 
Pharmacopoeia diffusion apparatus resulted in a greater apparent release constant and 
release rate for the formulations. 
There are a number of possible explanations for the differences observed between the two 
diffusion systems. Due to the design of the two systems, less evaporation occurs from the 
European Pharmacopoeia diffusion apparatus than the Franz diffusion cells. The formation 
of air bubbles under the membrane surface during the course of the experiment is possible 
in the Franz cell which may reduce the surface area of contact between the formulation and 
the receptor fluid thus resulting in a smaller diffusional area and possibly a more erratic 
diffusion rate. 
Another possible reason for the lower values seen for the apparent release constants and 
release rates when using the Franz diffusion apparatus may be due to the experimental 
methodology adopted. The Franz cells were completely emptied at each sampling time 
and refilled with fresh receptor fluid in order to maintain sink conditions. A period of time 
therefore exists when the receptor fluid is not at 32°C but is at ambient temperature. This 
lower temperature may result in a smaller amount of ibuprofen diffusing across the 
membrane for the period of time it takes for the receptor fluid to reach 32°C. 
The drug concentration gradient is the driving force for diffusion and any increase in the 
drug concentration on the receptor side of the barrier would decrease the magnitude of the 
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gradient and retard further permeation. Sample collection from the Franz diffusion cell is a 
non-continuous process as the cells are completely emptied at each sampling time and 
refilled with fresh receptor fluid. Conversely, sample collection from the European 
Pharmacopoeia diffusion cells is a continuous process. In the case of the Franz diffusion 
cell, absolute sink conditions may not prevail for the entire experimental period because of 
accumulation of the permeant in the receptor phase before each sampling time. This may 
be a result of a higher concentration of ibuprofen present in the receptor fluid due to the 
relatively smaller receptor volume (7 ml) as compared to 1000 ml volume of the European 
Pharmacopoeia cell. 
The longer lag times observed over a greater range using the European Pharmacopoeia 
diffusion apparatus may be due to the formation of small air bubbles on the cells and over 
the diffusional membrane area. These air bubbles formed rapidly and may have been due 
to temperature equilibration between the cell which is at ambient temperature and the 
receptor fluid at 32°C. The receptor fluid flow created by the rotation of the paddles at 
100 rpm dislodged the air bubbles after approximately four hours. The diffusional area 
may therefore have been decreased in a non-uniform fashion resulting in longer lag time 
values over a greater range. 
4.3.4.2 Conclusion 
The European Pharmacopoeia diffusion apparatus was judged to be the better of the two 
diffusion techniques assessed for the measurement of the amount of ibuprofen released 
from a topical formulation during in vitro testing. The European Pharmacopoeia diffusion 
apparatus shows better reproducibility, superior sink conditions and the larger values 
obtained for the amount of permeant diffusing across the membrane suggests that the 
system is more sensitive to the assessment of formulations of lower concentrations. 
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4.4 THE PERMEATION OF IBUPROFEN THROUGH SHED SNAKE SKIN AS 
THE BIOLOGICAL ANIMAL MEMBRANE 
4.4.1 Introduction 
Recently there has been considerable interest in the use of shed snake skin as a membrane 
for in vitro diffusion studies assessing the release of a number of drugs from semi-solid 
formulations. In this experiment shed snake skin from four species of snake was used for 
the verification of the usefulness, or otherwise, of shed snake skin as a biological 
membrane for the assessment of the in vitro permeation of ibuprofen. These were Naja 
nivea (Cape cobra), Naja haje haje (Egyptian cobra), Naja melanoleuca (forest cobra), and 
Python sebae natalensis (African rock python). 
This study was designed to evaluate the barrier characteristics of four different species of 
shed snake skin and to investigate the differences, if any, between the dorsal and ventral 
skin sites, the scale and hinge regions and the orientation of the skin. Evaluation of an 
appropriate diffusion technique for the measurement of the amount of ibuprofen released 
from a topical formulation during in vitro testing was also assessed. 
Ibuleve Gel (SA) was the formulation used in all the experiments. Of the two proprietary 
ibuprofen-containing topical formulations available in South Africa, Ibuleve Gel proved to 
be advantageous both economically and compositionally. Deep Relief Gel contains 3% 
levomenthol which may absorb in the same wavelength range as ibuprofen and therefore 
produce interference and was consequently not chosen for use. 
Each of the four species of shed snake skins were assessed using the Franz and European 
Pharmacopoeia diffusion cells. The data obtained from the infinite dose experiments were 
plotted as the cumulative amount of drug per centimetre squared appearing in the receptor 
compartment as a function of time. Typically, these plots displayed an initial lag phase, 
during which no drug appeared in the receptor compartment, followed by a phase in which 
the cumulative amount transported was linearly related to time. This profile is consistent 
with steady-state Fickian diffusion through a membrane following a lag phase. 
Accordingly, the data was analysed using the appropriate equations for Fickian diffusion. 
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4.4.2 Results Obtained Using the Franz Diffusion Cell 
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Figure 4.16 Ibuprofen diffusion profiles of four species of shed snake skin obtained 
using the Franz diffusion cell apparatus 
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Figure 4.17 Ibuprofen diffusion profile of each shed snake skin orientation obtained 
using the Franz diffusion cell apparatus 
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It can be seen from figure 4.16 that all four species of snake produce shed skins which 
display different characteristics as diffusion membranes. In all four species it appears that 
the cumulative amount of ibuprofen released per square centimetre of membrane decreases 
in the following order: dorsal membrane with the outside surface in contact with the 
formulation, ventral with outside surface contact, ventral with inside surface contact and 
dorsal with inside surface contact. The apparent release constants (Table 4.5), obtained 
from regression analysis of the diffusion curves, display the same trend. The lag time is 
similar for all four species of snake regardless of the orientation of the membrane with 
regard to the formulation. 
The dorsal membrane of the African rock python with outside surface contact is not 
significantly different at a 95% confidence interval to the ventral membrane with outside 
surface contact. However, the two outside orientations are significantly different to the two 
inside orientations. The ventral inside surface is not significantly different to the dorsal 
inside surface as a diffusion membrane. The apparent release constants range from 
173.09 J.lg/cm2 /b1l2 for the dorsal outside orientation to 54.20 J.lg/cm2 IhII2 for the dorsal 
inside orientation. The correlation coefficients are in the range of 0.8789 to 0.9466. 
The dorsal membrane of the Forest cobra with outside surface contact is significantly 
different to the ventral membrane with outside surface contact. However, the ventral 
outside surface is not significantly different to the ventral inside surface which is itself not 
significantly different to the dorsal inside surface. The apparent release constants range 
from 116.83 J.lg/cm2 /b I12 for the dorsal outside orientation to 43.23 J.lg/cm2 /b1l2 for the 
dorsal inside orientation. The correlation coefficients are in the range of 0.9248 to 0.9573. 
The dorsal membrane of the Egyptian cobra with outside surface contact is not 
significantly different to the ventral membrane with outside surface contact which is itself 
not significantly different to the ventral inside surface. However, the ventral inside surface 
is significantly different to the dorsal inside surface. The apparent release constants range 
from 60.93 J.lg/cm2 /b1l2 for the dorsal outside orientation to 21.29 J.lg/cm2 /bI12 for the dorsal 
inside orientation. The correlation coefficients are in the range of 0.8786 to 0.9120. 
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The dorsal membrane of the Cape cobra with outside surface contact is not significantly 
different to the ventral membrane with outside surface contact. However, the two outside 
orientations are significantly different to the two inside orientations. The ventral inside 
surface is significantly different to the dorsal inside surface as a diffusion membrane. The 
apparent release constants range from 37.93 Ilg/cm2 /h1l2 for the dorsal outside orientation 
to 9.69 Ilg/cm2 /h1l2 for the dorsal inside orientation. The correlation coefficients are in the 
range of 0.8949 to 0.9882. 
It can be seen from figure 4.17 that all four species of snake produce shed skins which 
appear to display different characteristics as diffusion membranes according to the 
orientation of the membrane. In all four orientations the cumulative amount of ibuprofen 
released per square centimetre of membrane decreases in the following order: African rock 
python, forest cobra, Egyptian cobra and Cape cobra. The apparent release constants 
(Table 4.5), obtained from regression analysis of the diffusion curves, display the same 
trend. 
The dorsal membrane of the African rock python with the outside surface in contact with 
the formulation is not significantly different to the dorsal outside membrane of the forest 
cobra. The dorsal outside membrane of the forest cobra is significantly different to the 
dorsal outside membrane of the Egyptian cobra, which is significantly different to the Cape 
cobra. The apparent release constants range from 173.09 Ilg/cm2 /h 112 for the dorsal outside 
orientation of the African rock python to 37.93 Ilg/cm2 /h 112 for the dorsal outside 
orientation of the Cape cobra. 
The dorsal membrane of the African rock python with the inside surface in contact with the 
formulation is not significantly different to the dorsal inside membrane of the forest cobra. 
The dorsal inside membrane of the forest cobra is significantly different to the dorsal inside 
membrane of the Egyptian cobra, which is significantly different to the Cape cobra. The 
apparent release constants range from 54.20 Ilg!cm2 /h 112 for the dorsal inside orientation of 
the African rock python to 9.69 Ilg/cm2 /h 112 for the dorsal inside orientation of the Cape 
cobra. 
All four species of snake produce shed skins orientated with the ventral outside surface in 
contact with the formulation, which are significantly different from each other. The 
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apparent release constants range from 114.13 ~g/cm2 /hI!2 for the ventral outside orientation 
of the African rock python to 33.13 ~g/cm2 /hI!2 for the ventral outside orientation of the 
Cape cobra. 
The ventral membrane of the African rock python with the inside surface in contact with 
the formulation is not significantly different to the ventral inside membrane of the forest 
cobra which is not significantly different to the ventral inside surface of the Egyptian 
cobra. The ventral inside surface of the Egyptian cobra is significantly different to the 
ventral inside surface of the Cape cobra. The apparent release constants range from 
90.40 ~g/cm2 /h 112 for the ventral inside orientation of the African rock python to 
25.5 ~g/cm2 IhI!2 for the ventral inside orientation of the Cape cobra. 
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SPECIES OF APPARENT RELEASE LAG TIME r1. 
SNAKE CONSTANT (J.lg[cm2 /hI/2) (hI/2) 
African rock python 173.09 1.22 0.9466 
Dorsal outside 
African rock python 54.20 1.23 0.9342 
Dorsal inside 
African rock python 114.13 1.42 0.9138 
Ventral outside 
African rock python 90.40 1.52 0.8789 
Ventral inside 
Forest cobra 116.83 1.23 0.9422 
Dorsal outside 
Forest cobra 43.23 1.01 0.9573 
Dorsal inside 
Forest cobra 76.96 1.25 0.9301 
Ventral outside 
Forest cobra 48.67 1.21 0.9248 
Ventral inside 
Egyptian cobra 60.93 1.50 0.8940 
Dorsal outside 
Egyptian cobra 21.29 1.30 0.9120 
Dorsal inside 
Egyptian cobra 49.69 1.54 0.8786 
Ventral outside 
Egyptian cobra 42.05 1.43 0.9015 
Ventral inside 
Cape cobra 37.93 1.27 0.8949 
Dorsal outside 
Cape cobra 9.69 1.17 0.9397 
Dorsal inside 
Cape cobra 33.13 1.12 0.9336 
Ventral outside 
Cape cobra 25.50 1.39 0.9882 
Ventral inside 
Table 4.5 The release constants, lag times and r2 values for ibuprofen diffusing 
through four species of shed snake skin, using the Franz diffusion cell 
apparatus 
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4.4.3 Results Obtained Using the European Pharmacopoeia Diffusion Cell 
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Figure 4.18 Ibuprofen diffusion profiles of four species of shed snake skin obtained 
using the European Pharmacopoeia diffusion cell apparatus 
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Figure 4.19 Ibuprofen diffusion profile of each shed snake skin orientation obtained 
using the European Pharmacopoeia diffusion cell apparatus 
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It can be seen from figure 4.18 that all four species of snake produce shed skins which 
display different characteristics as diffusion membranes. The cumulative amount of 
ibuprofen released per square centimetre of membrane at 72 hours does not decrease in the 
same order for each species of snake as was the case with the diffusion profiles obtained 
from the Franz diffusion cell apparatus. However, certain patterns of release have 
emerged. Most permeable is the ventral outside surface in contact with the formulation in 
three of the species investigated and least permeable is the dorsal inside membrane, which 
was found to be true for all four species. The apparent release constants (Table 4.6), 
obtained from regression analysis of the diffusion curves, display the same trends. The lag 
times are similar for all four species of snake regardless of the orientation of the membrane 
with the exception of the cape cobra dorsal inside and ventral outside orientations, which 
are roughly half those of the other reported values. 
The ventral membrane of the African rock python with outside surface contact is 
significantly different at a 95% confidence interval to the dorsal membrane with outside 
surface contact. However, the dorsal outside and ventral inside orientations are not 
significantly different from one another, but are significantly different from the dorsal 
inside membrane in contact with the formulation. The apparent release constants range 
from 276.65 Ilg/cm2/h112 for the ventral outside orientation to 102.79 Ilglcm2/h1l2 for the 
dorsal inside orientation. The correlation coefficients are in the range of 0.9226 to 0.9456. 
The dorsal membrane of the Forest cobra with outside surface contact is not significantly 
different to the ventral membrane with outside surface contact. However, the ventral 
outside surface is significantly different to the ventral inside surface which is itself 
significantly different to the dorsal inside surface. The apparent release constants range 
from 202.09 Ilg/cm2/h1l2 for the dorsal outside orientation to 57.59 Ilg/cm2/h112 for the 
dorsal inside orientation. The correlation coefficients are in the range of 0.9261 to 0.9401. 
The ventral membrane of the Egyptian cobra with outside surface contact is significantly 
different to the ventral membrane with inside surface contact which is itself significantly 
different to the dorsal outside surface. However, the dorsal outside surface is not 
significantly different to the dorsal inside surface. The apparent release constants range 
from 111.79 Ilg/cm2/h1l2 for the ventral outside orientation to 55.77 Ilg/cm2 Ihll2 for the 
dorsal inside orientation. The correlation coefficients are in the range of 0.8844 to 0.9336. 
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All four orientations of the Cape cobra shed skins are significantly different from one 
another. The ventral membrane with the outside surface in contact with the formulation is 
most permeable followed by the dorsal outside and ventral outside orientations which 
display very similar diffusion profiles. The dorsal inside orientation is least permeable 
once again. The apparent release constants range from 95.92 J.lg/cm2 /h1l2 for the ventral 
outside orientation to 17.95 J.lg/cm2 Ih1l2 for the dorsal inside orientation. The correlation 
coefficients are in the range of 0.9019 to 0.9840. 
It can be seen from figure 4.19 that all four species of snake produce shed skins which 
appear to display different characteristics as diffusion membranes according to the 
orientation of the membrane. In all four orientations the cumulative amount of ibuprofen 
released per square centimetre of membrane decreases in the same order as that observed 
using the Franz diffusion cell apparatus: African rock python, forest cobra, Egyptian cobra 
and Cape cobra. The apparent release constants (Table 4.6), obtained from regression 
analysis of the diffusion curves, display the same trend. 
The dorsal membrane of the African rock python with the outside surface in contact with 
the formulation is not significantly different to the dorsal outside membrane of the forest 
cobra. The dorsal outside membrane of the forest cobra is significantly different to the 
dorsal outside membrane of the Egyptian cobra, which is significantly different to the Cape 
cobra. The African rock python and forest cobra are very much more permeable than the 
Egyptian and Cape cobra. The apparent release constants range from 205.57 J.lg/cm2 /h1l2 
for the dorsal outside orientation of the African rock python to 51.89 J.lg/cm2 /h 112 for the 
dorsal outside orientation of the Cape cobra. 
The dorsal membrane of the African rock python with the inside surface in contact with the 
formulation is significantly different to the dorsal inside membrane of the forest cobra. 
The dorsal inside membrane of the forest cobra is not significantly different to the dorsal 
inside membrane of the Egyptian cobra and in fact the two membranes display very similar 
permeabilities. The Cape cobra is significantly different to the Egyptian cobra. The 
apparent release constants range from 102.79 J.lg/cm2 /h 112 for the dorsal inside orientation 
of the African rock python to 17.95 J.lg/cm2 /h1l2 for the dorsal inside orientation of the 
Cape cobra. 
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The ventral membrane of the African rock python with the outside surface in contact with 
the formulation is significantly different to the ventral outside membrane of the forest 
cobra which is significantly different to the ventral outside surface of the Egyptian cobra. 
The ventral outside surface of the Egyptian cobra is not significantly different to the 
ventral outside surface of the Cape cobra. The apparent release constants range from 
276.65 J..lg/cm2 /h1l2 for the ventral outside orientation of the African rock python to 
95.92 J..lg/cm2 /h l12 for the ventral outside orientation of the Cape cobra. 
All four species of snake produce shed skins orientated with the ventral inside surface in 
contact with the formulation, which are significantly different from each other. The 
apparent release constants range from 192.92 J..lg/cm2 /h 1/2 for the ventral inside orientation 
of the African rock python to 48.35 J..lg/cm2 /h 112 for the ventral inside orientation of the 
Cape cobra. 
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SPECIES OF APPARENT RELEASE LAG TIME r2 
SNAKE CONSTANT (J,Lg/cm2 /h1l2) (hI/2) 
African rock python 205.57 1.30 0.9321 
Dorsal outside 
African rock python 102.79 1.17 0.9456 
Dorsal inside 
African rock python 276.65 1.27 0.9407 
Ventral outside 
African rock python 192.92 1.27 0.9226 
Ventral inside 
Forest cobra 202.09 1.30 0.9287 
Dorsal outside 
Forest cobra 57.59 1.16 0.9261 
Dorsal inside 
Forest cobra 198.38 1.13 0.9401 
Ventral outside 
Forest cobra 117.78 1.14 0.9312 
Ventral inside 
Egyptian cobra 64.87 1.35 0.8844 
Dorsal outside 
Egyptian cobra 55.77 1.16 0.9286 
Dorsal inside 
Egyptian cobra 111.79 1.37 0.9098 
Ventral outside 
Egyptian cobra 70.90 1.15 0.9336 
Ventral inside 
Cape cobra 51.89 1.40 0.9019 
Dorsal outside 
Cape cobra 17.95 0.61 0.9840 
Dorsal inside 
Cape cobra 95.92 0.58 0.9773 
Ventral outside 
Cape cobra 48.35 1.22 0.9310 
Ventral inside 
Table 4.6 The release constants, lag times and r2 values for ibuprofen diffusing 
through four species of shed snake skin, using the European Pharmacopoeia 
diffusion cell apparatus 
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4.4.4 Diffusion Through the Scale and Hinge Regions of Shed Snake Skin 
Shed snake skin is composed of two very different regions. These comprise the scales 
which are separated by hinges. The scales are fairly rigid, whereas the hinge region is 
relatively elastic. Generally, the ventral scales are much larger than the dorsal scales 
resulting in a much larger hinge:scale ratio for dorsal skin than for ventral skin. Since 
permeation appears to be more facile through dorsal skin, it may imply that diffusion 
occurs mainly through the hinge region of the skin. 
The in vitro diffusion experiments to investigate the differences, if any, between the scale 
and hinge regions of the skin were performed in modified Franz cells (88,169) with a 
reduced diffusional area (0.44cm2) using African rock python ventral skin with the outside 
surface in contact with the formulation. The African rock python species was chosen 
because the ventral scales were the largest of all four species with the outside orientation 
giving a greater release rate than the inside orientation. Two experiments utilising five 
Franz cells each were performed. One experiment orientated the shed snake skin 
membrane so that only the scale region was in contact with the formulation and thus only 
the scale was used as the diffusional membrane. The second experiment orientated the 
shed snake skin membrane so that the hinge plus scale regions were in contact with the 
formulation. 100 mg of 5% ibuprofen gel (Ibuleve, South Africa) was placed in the donor 
compartment. The cells were maintained at 32°C (n=5) throughout the 72 hour period. 
The receptor fluid (0.2M phosphate buffer at pH 7.2) was analysed for ibuprofen at 2, 4,8, 
24, 48 and 72 hours by the hplc method described. The Franz cells were completely 
emptied at each sampling time and refilled with fresh receptor fluid. The different 
diffusion profiles observed for the scale and hinge regions are shown in figure 4.20. 
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Figure 4.20 Ibuprofen diffusion profiles of the scale and hinge regions of shed snake 
skin 
Surprisingly, the results indicate that the scale region of shed snake skin is slightly but 
significantly more permeable to the diffusion of ibuprofen than the hinge region of the 
skin. Despite the fact that permeation appears to be more facile through dorsal skin, it does 
not imply that diffusion occurs mainly through the hinge region of the skin. 
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4.4.5 Results of Scanning Electron Microscopy 
The thickness of the skins (Table 4.7) shows some interesting trends. The ventral skin of 
all four species is always thicker than the dorsal skin. This is due to the fact that when the 
snake moves, the ventral surface is in contact with the ground. It would therefore have to 
be more robust than the dorsal surface. The hinge region was observed to be considerably 
thinner than the scale region. The elasticity of the hinge region is illustrated in Figure 4.23 
which is contrasted with the rigidity of the scale region (Figure 4.22). It is interesting to 
compare and contrast the shed snake skin thicknesses to those of synthetic membranes. 
The O.4f.lm filter membrane is closest in thickness, while the silicone diffusion membrane 
(Figure 4.21) is roughly five times thicker than the shed snake skins. The thicknesses of 
the scale area of the shed snake skins and the filter and silicone membranes were 
determined from the electron micrographs of the transverse sections. 
MEMBRANE DORSAL SCALE VENTRAL SCALE 
THICKNESS (f.lm) THICKNESS (f.lm) 
African rock python 23.8 33.1 
Forest cobra 13.8 30.0 
Egyptian cobra 15.6 21.3 
Cape cobra 7.5 32.5 
O.4f.lm Filter membrane 10.0 
Silastic silicone membrane 156.0 
Table 4.7 Membrane thickness 
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Figure 4.21 Transverse section of silastic 
silicone membrane 
Figure 4.23 Transverse section of dorsal 
forest cobra hinge 
Figure 4.24 Dorsal Egyptian cobra hinge 
(inside surface) 
Figure 4.22 Transverse section of 
ventral forest cobra 
Figure 4.25 Dorsal Cape cobra 
hinge (outer surface) 
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Figure 4.26 Dorsal African rock python 
scale (inside surface) 
Figure 4.28 Dorsal Egyptian cobra scale 
(inside surface) 
Figure 4.30 Surface region of 0.4 ~m 
filter membrane 
Figure 4.27 Dorsal forest cobra scale 
scale (inside surface) 
Figure 4.29 Dorsal Cape cobra scale 
(inside surface) 
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Typical electron micrographs of the surface topography are illustrated in Figures 4.24 to 
4.30. The electron micrographs of the surface topography of the three cobra species 
showed the same type of structure for the hinge and scale regions respectively. The 
outside surface of the dorsal membrane and the ventral outside surface of the hinge areas 
were found to be similar in structure as were the dorsal inside and ventral inside hinge 
orientations. The dorsal outside and the ventral outside surfaces of the scale regions were 
found to be similar in structure as were the dorsal inside and ventral inside surfaces of the 
scales. The ventral scales are very much larger than the dorsal scales in all four snake 
species therefore there is a much larger hinge:scale ratio for dorsal skin than there is for 
ventral skin. 
As the electron micrographs show, the surface topography of the African rock python skin 
is completely different to the cobra skins, however a pattern of similarity emerged between 
the different orientations of the hinge areas of the African rock python. The dorsal outside 
and the ventral outside surfaces of the hinge areas were found to be similar in structure as 
were the dorsal inside and ventral inside hinge surfaces. The dorsal outside and inside 
surfaces were found to be similar, while the ventral outside and inside surfaces differed not 
only from one another but from all the other surfaces as well. 
High magnification electron microscopic examination of larger areas of the dorsal and 
ventral scale and hinge areas of the inner and outer surfaces of the skins of all four species 
indicated that there are no pores present. This may be contrasted with the filter membrane 
of the smallest pore size used in this study (Figure 4.30). 
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4.4.6 Discussion 
The electron micrographs of the transverse sections of the shed snake skin show that no 
correlation was seen between the thickness of the ventral and dorsal skins respectively of 
all four species and the diffusion of ibuprofen through these membranes. Another deviation 
from the correlation between thickness and release of ibuprofen is that the thickness of 
both the dorsal and ventral sections of the African rock python skin is greater than the 
thickest cobra skin yet the African rock python species produces the greatest release profile 
of all four species. The differences in the skin composition may therefore be a reason for 
the different diffusion characteristics displayed by the shed snake skin membranes. The 
chemical composition of the different shed snake skins was not elucidated in this study. 
The difference in the structure of the snake skins as illustrated by the electron micrographs 
of the surface topography may also be a reason for the different diffusion characteristics. 
The three cobra species showed similar diffusion characteristics that were different from 
those of the African rock python. The dorsal and ventral outside surfaces of both the hinge 
and scale regions of the cobra species show similar structures. These regions produce a 
greater rate of diffusion of ibuprofen when using both the Franz and European 
Pharmacopoeia diffusion cells compared to the dorsal and ventral inside surfaces of both 
the hinge and scale regions. The inside surfaces of these regions show similar structures 
but produce a lower rate of diffusion. 
Permeation through shed snake skin differs depending on the orientation of the membrane 
with respect to the formulation and the receptor fluid. This is a difficult aspect of the 
results to explain but it might be that the outside surface of the membrane in contact with 
the formulation presents less of a barrier to the diffusing drug molecules than the inside 
surface in contact with the formulation. The differences in release may be explained by the 
structure of shed snake skin which consists of three distinctive layers (113). These are the 
beta-keratin-rich outermost beta layer, alpha-keratin- and lipid-rich intermediate mesos 
layer, and alpha-keratin-rich innermost alpha layer (149). Further, the mesos layer shows 
three to five layers of multilayer structure with cornified cells surrounded by intercellular 
lipids, which is similar to human stratum corneum. This mesos layer is also a major depot 
of lipids, and the mesos layer and alpha layer are considered to be the main barrier to water 
and thus ibuprofen penetration through the skin (172,180-186). However, when ibuprofen 
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diffuses through the outside surface of the membrane it diffuses through the beta and alpha 
protein layers as well as the mesos lipid layer before coming into contact with the inside 
membrane surface which appears to present no additional barrier. The differences in 
release may therefore be attributed to what is in contact with the membrane depending on 
its orientation i.e., the outside surface in contact with the formulation and the inside surface 
in contact with the receptor fluid and vice versa. It is therefore important that if shed snake 
skin is used as a membrane, the orientation should be identical for each sample. 
Shed snake skin is composed of two very different regions. These comprise the scales 
which are separated by hinges. The scales are fairly rigid, whereas the hinge region is 
relatively elastic. The scales on the dorsal surface are much smaller than the scales on the 
ventral surface and, in addition, the size of the scales varies considerably between species. 
The investigation into the difference in the diffusion of ibuprofen through the scale and 
hinge regions yielded interesting and unexpected results. Since permeation appears to be 
more facile through dorsal skin when investigated using the European Pharmacopoeia cell 
apparatus, it was assumed that diffusion occurred mainly through the hinge region of the 
skin and that a higher ratio of hinge to scale area existed for dorsal skin (111). These 
assumptions were found to be incorrect and in fact the opposite was true. Firstly, due to 
the placement of the ventral skin over the diffusional area of the Franz cell with the 
extended hinge occupying the central area and the adjacent scales covering the remaining 
diffusional area a hinge:scale area of approximately 1: 1 resulted. The dorsal scales are 
very much smaller than the ventral scales therefore a smaller ratio of hinge: scale was found 
for dorsal skin than for ventral skin when placing the membrane over the diffusional area 
of the Franz cell. Secondly, it was found that the scale region of shed snake skin is slightly 
but significantly more permeable to the diffusion of ibuprofen than the hinge region of the 
skin. A possible explanation may be that the relative fragility of the hinge region as 
compared to the scale region necessitates a greater barrier to water penetration and thus 
ibuprofen penetration provided by a modified mesos and alpha layer. 
The most permeable orientation of shed snake skin differs when the membrane is assessed 
using the Franz and European Pharmacopoeia diffusion cells. When assessed using the 
Franz diffusion cell apparatus the most permeable orientation is the dorsal outside surface 
in contact with the formulation as opposed to the ventral outside surface when assessed 
using the European Pharmacopoeia diffusion cells. This may be explained by the hinge to 
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scale area ratio. The cells of the European Pharmacopoeia have a surface area from which 
the formulation can diffuse that is five times larger than the corresponding surface area of 
the Franz cells. Due to the placement of the ventral skin over the diffusional area of the 
Franz cell with the extended hinge occupying the central area and the adjacent scales 
covering the remaining diffusional area a hinge:scale area of approximately I: I resulted. 
This may be contrasted with a hinge:scale area of approximately 0.5: 1 when using the 
European Pharmacopoeia cell. It was shown that diffusion of ibuprofen occurs mainly 
through the scale region of the skin, more scale to hinge area of ventral skin is exposed to 
the formulation in the European Pharmacopoeia cells thus resulting in greater release. 
The dorsal scales are very much smaller than the ventral scales therefore a smaller ratio of 
hinge:scale was found for dorsal skin than for ventral skin when placing the membrane 
over the diffusional area of the Franz cell. The dorsal outside orientation was therefore 
found to be more permeable than the ventral outside orientation when assessed using the 
Franz diffusion apparatus. 
The higher permeability of the African rock python skin may be due to a reduction in 
integrity because of the rough manner in which this snake sheds its skin by rubbing its 
body against rocks and thus removing the skin in fragments (111). This is however 
unlikely as the replicate determinations showed good reproducibility. 
High magnification electron microscopic examination of larger areas of all four species 
indicated that there are no pores present. The integrity of shed snake skin, as verified by 
electron microscopy, therefore indicates that it behaves as a diffusion membrane. The 
choice of the species of snake that produces shed skins that most closely mimic diffusion 
through a synthetic silicone diffusing membrane depends on the diffusion apparatus to be 
used in the experiment. When using the Franz diffusion cell it appears that the best shed 
snake skin of the four species investigated in terms of diffusion profile, apparent release 
constant, lag time and correlation coefficient is the African rock python orientated with the 
dorsal outside surface in contact with the formulation. When using the European 
Pharmacopoeia diffusion apparatus it appears that the African rock python orientated with 
the ventral outside surface in contact with the formulation most closely mimics a synthetic 
silicone diffusing membrane. 
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4.4.7 Conclusion 
Previous reports have described shed snake skin as a 'model' membrane, i.e. a membrane 
which shows similar permeability to human stratum corneum 003,104,108). The results 
reported here show clearly that, for ibuprofen, the four species of snake produce shed skin 
with completely different diffusion characteristics when all other conditions are identical. 
It may well be that there is one particular species of snake which produces shed skin of 
identical permeability to human stratum corneum, but to describe shed snake skin in 
general as a model membrane seems incorrect. It is therefore important that if shed snake 
skin is used as a membrane, the species, skin site and orientation should be reported. 
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4.4.8 Comparison of the Diffusion Cells 
4.4.8.1 Python sebae natalensis (African Rock Python) 
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4.4.8.2 Naja melanoleuca (Forest Cobra) 
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Figure 4.32 Ibuprofen diffusion profiles of the forest cobra 
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4.4.8.3 Naja haje haje (Egyptian Cobra) 
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Figure 4.33 Ibuprofen diffusion profiles of the Egyptian cobra 
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4.4.8.4 Naja nivea (Cape Cobra) 
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Figure 4.34 Ibuprofen diffusion profiles of the Cape cobra 
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4.4.8.5 Discussion 
The diffusion profiles obtained for each orientation of shed snake skin, utilising the Franz 
and European Pharmacopoeia diffusion cells, were compared in an attempt to demonstrate 
an appropriate diffusion technique for the measurement of the amount of ibuprofen 
diffusing across a biological membrane during in vitro testing. 
A statistically significant difference, at a 95% confidence interval, was seen between the 
diffusion profiles obtained using the Franz and the European Pharmacopoeia diffusion cells 
for all the shed snake skin orientations with the exception of the dorsal membrane of the 
African rock python and Egyptian cobra orientated such that the outside surface is in 
contact with the formulation. The percentage standard deviation using the Franz diffusion 
cells was greater than the European Pharmacopoeia diffusion cells. The standard deviation 
of the cumulative amount of ibuprofen released per centimetre squared was generally 
greater using the Franz diffusion cells. In all cases the use of the European Pharmacopoeia 
diffusion apparatus resulted in a greater apparent release constant. The possible 
explanations for the differences observed between the two diffusion systems have 
previously been discussed. 
Since it is possible that most diffusion occurs through the scale region of a shed snake skin 
the relatively large area of the European Pharmacopoeia diffusion cell may reduce the 
influence the hinge:scale area ratio may have on the diffusion of a drug molecule and may 
therefore be the apparatus of choice when using shed snake skin as a biological membrane. 
4.4.8.6 Conclusion 
The European Pharmacopoeia diffusion apparatus was judged to be the better of the two 
diffusion techniques assessed for the measurement of the amount of ibuprofen diffusing 
across the ventral outside orientation of shed skin during in vitro testing. The European 
Pharmacopoeia diffusion apparatus once again shows better reproducibility. The Franz 
diffusion apparatus was judged to be the better for the measurement of the amount of 
ibuprofen diffusing across the dorsal outside orientation of shed skin during in vitro testing. 
However, the choice of this diffusion apparatus must be weighed against the relatively poor 
reproducibility as compared with the European Pharmacopoeia diffusion apparatus. 
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APPENDIX I 
EXACT DRUG CONTENT OF THE FORMULATIONS AND STATISTICAL 
EVALUATION 
PRERARATION ACTUAL %RSD PERCENT 
PERCENTAGE OF DEVIATION 
ACTIVE (n=3) 
Deep Relief Gel (SA) 4,36 1.86 12.8 
Ibuleve Gel (SA) 4,31 1.98 13.8 
Deep Relief Gel (UK) 4,31 1.75 13.8 
Ibuleve Gel (UK) 4,38 1.73 12.4 
Ibuleve Mousse (UK) 4,38 2.08 12.4 
Nurofen Gel (UK) 4,34 1.59 13.2 
Proflex Cream (UK) 4,54 2.22 9.2 
Radian B Gel (UK) 4,42 1.92 11.6 
Ralgex Gel (UK) 4,32 1.83 13.6 
Cliptol Gel (FR) 4,41 1.49 11.8 
Dolgit Cream (FR) 4,32 2.41 13.6 
Ibutop Gel (FR) 4,34 1.73 13.2 
Intralgis Gel (FR) 4,51 1.97 9.8 
Syntofene Gel (FR) 4,34 1.48 13.2 
Tiburon Gel (FR) 4,48 1.79 10.4 
One-way analysis of variance (Tukey test) 
Source of variation Degrees of freedom Sum of squares Mean square 
Treatments 14 5.772E+ll 4.123E+1O 
(between columns) 
Residuals 30 5.101E+11 1.700E+1O 
(within columns) 
Total 44 1.087E+12 
F = 2.425 
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APPENDIX II 
COMPOSITION OF FORMULATIONS 
PREPARATION (5% mlm) MANUFACTURED COMPOSITION 
Ibuleve Gel South Africa Industrial methylated spirit 
(BP) 
Carbomer 
Propylene glycol (BP) 
Diethylamine 
Purified water 
Deep Relief Gel United Kingdom Levomenthol 3% mlm 
Carbomer 
Propylene glycol 
Di-isopropanolamine 
Ethanol 
Purified water 
Ibuleve Gel United Kingdom Industrial methylated spirit 
(BP) 
Carbomer 
Propylene glycol (BP) 
Diethylamine 
Purified water 
Ibuleve Mousse United Kingdom Carbomer 
Propylene glycol (BP) 
Phenoxyethanol (BP) 
Diethylamine 
Butane 40 
Purified water 
Nurofen Gel United Kingdom Ethanol 
Propylene glycol 
Di -isopropanolamine 
Carbomer 
Purified water 
Proflex Cream United Kingdom Coconut oil 
Glyceryl stearate 
Polyoxyethylene fatty acid 
Ester 
Propylene glycol 
Xanthan gum 
Parabens 
Purified water 
Radian B Gel United Kingdom Hydroxyethylcellulose 
Sodium hydroxide 
Benzyl alcohol 
Isopropyl alcohol 
Purified water 
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Ralgex Gel United Kingdom Isopropyl alcohol 
Solketal 
Poloxamer 407 
Miglyo1812 
Lavender oil 
Neroli oil/orange tree flower 
oil 
Purified water 
Cliptol Gel France Levomentho13% 
Proplylene glycol 
Di -isopropanalamine 
Carbomere 980 
96% ethanol 
Purified water 
Dolgit Cream France Triglycerides of average 
carbon chain length (miglyol 
812) 
Mixture of glyceryl stearates 
and monostearates 
Polyoxyethylene esters 
(Arlacel 165) 
Polyoxyethylene esters of 
fatty acids (Arlatone 983 s) 
Propylene glycol 
Xanthane gum (Keltrol F) 
Lavender oil 
Neroli oil 
Purified water 
Ibutop Gel France Isopropyl alcohol 
Glycerol isopropylidene 
(Solketal) 
Poloxamere 407 (Pluronic 
F127) 
Neutral oil (Miglyol 812) 
Lavender essence 
Artificial essence of Orange 
tree flower 
Purified water 
Intralgis Gel France Isopropyl alcohol 
Hydroxyethylcellulose 
Sodium hydroxide 
Benzyl alcohol 
Purified water 
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Syntofene Gel France Isopropyl alcohol 
Hydroxyethylcellulose 
Sodium hydroxide 
Benzyl alcohol 
Purified water 
Tiburon Gel France Isopropyl alcohol 
H ydroxyethylcellulose 
Sodium hydroxide 
Benzyl alcohol 
Purified water 
131 
APPENDIX III 
RAW DATA USED TO ASSESS THE PROPRIETARY IBUPROFEN-
CONTAINING TOPICAL 
PREPARATIONS FROM THREE COUNTRIES 
Franz diffusion cell apparatus: 
Total amount liberated in J..lg/cm2 
( )=standard deviation 
n=5 
Silastos silicone membrane 
Time Dolgit Proflex Ralgex 
cream cream gel 
Ibutop Ibuleve Deep 
gel gel Relief 
FR UK UK FR UK gel SA 
0 0 0 0 0 0 0 
2 201 170 451 447 157 167 
(29) (23) (19) (40) (18) (17) 
4 374 320 700 681 260 296 
(33) (38) (18) (57) (30) (25) 
8 684 594 1061 1044 387 455 
(52) (67) (19) (131) (52) (35) 
24 1550 1460 1860 1816 951 650 
(82) (89) (48) (162) (200) (58) 
48 2172 2138 2260 2201 1643 1126 
(49) (55) (76) (119) (160) (230) 
72 2450 2377 2383 2295 1889 1537 
(58) (53) (82) (105) (151) (491) 
Time Deep Cliptol Ibuleve Tiburon Intralgis 
Relief gel gel Mousse gel gel 
UK FR UK FR FR 
0 0 0 0 0 0 
2 182 222 124 24 127 
(17) (27) (14) (3) (6) 
4 338 380 202 44 177 
(35) (37) (18) (5) (6) 
8 499 543 298 68 207 
(45) (37) (24) (6) (7) 
24 718 763 487 112 231 
(65) (38) (56) (18) (11) 
48 871 1066 745 208 267 
(85) (114) (92) (81) (14) 
72 987 1247 986 315 306 
(137) (145) (164) (125) (18) 
Ibuleve Nurofen 
gel gel 
SA UK 
0 0 
128 132 
(25) (17) 
201 239 
(32) (24) 
311 380 
(82) (36) 
608 734 
(181) (178) 
1157 1141 
(378) (380) 
1437 1399 
(355) (565) 
Radian B Syntofene 
gel gel 
UK FR 
0 0 
50 76 
(5) (11) 
83 104 
(6) (9) 
114 130 
(7) (7) 
146 155 
(5) (5) 
204 191 
(37) (26) 
267 284 
(59) (65) 
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European Pharmacopoeia diffusion cell apparatus: 
Total amount liberated in J..lg/cm2 
( )=standard deviation 
n=5 
Silastos silicone membrane 
Time Dolgit Proflex Ralgex Ibutop Ibuleve Deep 
cream cream gel gel gel Relief 
FR UK UK FR UK gel SA 
0 0 0 0 0 0 0 
2 570 460 590 690 680 370 
(0) (0) (0) (100) (100) (0) 
4 780 640 840 970 940 530 
(0) (100) (0) (l00) (0) (0) 
8 1110 930 1210 1340 1210 700 
(l00) (100) (0) (100) (0) (100) 
24 2060 1850 1970 2090 1660 1060 
(200) (300) (100) (100) (l00) (l00) 
48 2810 2600 2350 2410 2120 1360 
(200) (100) (200) (100) (200) (100) 
72 2960 2930 2480 2510 2600 1580 
(200) (100) (200) (100) (100) (100) 
Time Deep Cliptol Ibuleve Tiburon Intralgis 
Relief gel gel Mousse gel gel 
UK FR UK FR FR 
0 0 0 0 0 0 
2 530 600 230 290 350 
(0) (0) (0) (0) (0) 
4 680 810 300 340 350 
(100) (l00) (100) (0) (0) 
8 900 1060 410 340 370 
(0) (100) (200) (0) (0) 
24 1280 1530 810 430 510 
(100) (100) (300) (0) (l00) 
48 1640 1870 1200 490 680 
(0) (l00) (300) (0) (100) 
72 1860 2150 1620 590 790 
(100) (100) (400) (100) (200) 
Ibuleve Nurofen 
gel gel 
SA UK 
0 0 
360 450 
(0) (0) 
540 650 
(100) (l00) 
760 920 
(100) (0) 
1250 1330 
(0) (l00) 
1690 1700 
(100) (0) 
2080 1920 
(200) (0) 
Radian B Syntofene 
gel gel 
UK FR 
0 0 
60 250 
(0) (0) 
80 250 
(0) (0) 
110 290 
(0) (0) 
210 380 
(0) (0) 
350 470 
(100) (100) 
460 550 
(100) (100) 
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Franz diffusion cell apparatus: 
Diffusion rate in Ilglh 
( )=standard deviation 
n=5 
Silastos silicone membrane 
Time Dolgit Proflex 
cream cream 
FR UK 
1 165 140 
(23) (19) 
3 143 124 
(7) (12) 
6 127 112 
(9) (12) 
16 89 89 
(5) (4) 
36 43 47 
(4) (5) 
60 19 16 
(4) (6) 
Time Deep Cliptol 
Relief gel gel 
UK FR 
1 150 183 
(14) (22) 
3 128 130 
(20) (9) 
6 66 67 
(5) (2) 
16 22 23 
(3) (2) 
36 10 20 
(1) (6) 
60 7 12 
(4) (2) 
Ralgex Ibutop Ibuleve Deep Ibuleve Nurofen 
gel gel gel Relief gel gel 
UK FR UK gel SA SA UK 
371 369 129 137 105 108 
(15) (33) (15) (14) (20) (14) 
206 192 84 105 60 88 
(8) (15) (11) (9) (7) (7) 
148 150 52 65 45 58 
(6) (26) (10) (5) (22) (6) 
82 80 58 20 30 36 
(4) (5) (20) (3) (16) (20) 
27 26 47 32 37 27 
(5) (6) (9) (17) (16) (18) 
8 7 16 28 19 17 
(2) (2) (4) (18) (7) (14) 
Ibuleve Tiburon Intralgis Radian B Syntofene 
Mousse gel gel gel gel 
UK FR FR UK FR 
102 19 105 42 63 
(11) (3) (5) (4) (9) 
65 17 41 26 23 
(4) (2) (2) (1) (2) 
40 10 12 13 11 
(7) (0.5) (1) (0.5) (2) 
19 4 3 3 3 
(4) (2) (0.5) (0.5) (0.5) 
17 7 3 4 3 
(3) (5) (0.5) (3) (1) 
16 7 3 4 6 
(5) (3) (0.5) (2) (3) 
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European Pharmacopoeia diffusion cell apparatus: 
Diffusion rate in /-lg/h 
( )=standard deviation 
n=5 
Silastos silicone membrane 
Time Dolgit Proflex 
cream cream 
FR UK 
1 1934 1582 
(950) (780) 
3 725 608 
(369) (439) 
6 571 499 
(291) (283) 
16 407 391 
(206) (204) 
36 212 214 
(113) (121) 
60 43 93 
(29) (52) 
Time Deep Cliptol 
Relief gel gel 
UK FR 
1 2164 2060 
(144) (1020) 
3 643 691 
(282) (356) 
6 432 443 
(120) (221) 
16 198 200 
(48) (99) 
36 121 95 
(20) (49) 
60 76 80 
(22) (45) 
Ralgex Ibutop Ibuleve Deep 
gel gel gel Relief 
UK FR UK gel SA 
2009 2849 2317 1519 
(985) (210) (1157) (155) 
847 1138 893 670 
(416) (205) (474) (91) 
640 751 464 335 
(316) (24) (248) (91) 
323 386 193 188 
(167) (30) (104) (14) 
110 107 130 102 
(58) (34) (82) (20) 
37 36 138 75 
(25) (10) (84) (24) 
Ibuleve Tiburon Intralgis 
Mousse gel gel 
UK FR FR 
786 1186 1182 
(402) (125) (583) 
236 215 2 
(213) (192) (1) 
192 11 50 
(258) (3) (30) 
172 49 59 
(114) (26) (36) 
110 21 47 
(56) (4) (36) 
120 33 33 
(68) (14) (32) 
Ibuleve Nurofen 
gel gel 
SA UK 
1220 1834 
(613) (201) 
637 814 
(336) (270) 
369 552 
(202) (104) 
209 214 
(106) (43) 
124 126 
(66) (25) 
111 74 
(56) (19) 
Radian B Syntofene 
gel gel 
UK FR 
177 690 
(139) (537) 
34 6 
(33) (4) 
47 51 
(39) (52) 
32 30 
(26) (24) 
33 21 
(37) (21) 
25 19 
(20) (17) 
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APPENDIX IV 
RAW DATA USED TO ASSESS DIFFUSION OF IBUPROFEN THROUGH SHED 
SNAKESKIN 
Franz diffusion cell apparatus: 
Total amount liberated in Ilg/cm2 
( )=standard deviation 
n=5 
AFRICAN ROCK PYTHON 
Time Dorsal Dorsal Ventral 
outside inside outside 
0 0 0 0 
2 12 8 5 
(12) (3) (1) 
4 64 20 15 
(42) (3) (3) 
8 138 45 49 
(57) (4) (8) 
24 522 140 277 
(239) (21) (30) 
48 1011 331 626 
(347) (65) (70) 
72 1373 429 928 
(472) (112) (90) 
EGYPTIAN COBRA 
Time Dorsal Dorsal Ventral 
outside inside outside 
0 0 0 0 
2 3 3 1 
(1) (1) (1) 
4 7 7 4 
(2) (1) (1) 
8 12 17 12 
(6) (2) (3) 
24 131 51 94 
(43) (5) (17) 
48 326 113 258 
(68) (9) (21) 
72 501 180 416 
(95) (17) (16) 
Ventral 
inside 
0 
3 
(1) 
20 
(5) 
35 
(6) 
145 
(36) 
352 
(110) 
599 
(177) 
Ventral 
inside 
0 
3 
(1) 
7 
(2) 
17 
(2) 
94 
(43) 
225 
(81) 
349 
(119) 
FOREST COBRA 
Dorsal Dorsal Ventral Ventral 
outside inside outside inside 
0 0 0 0 
11 12 11 12 
(3) (2) (2) (1) 
43 28 27 26 
(17) (6) (10) (2) 
104 59 64 57 
(40) (18) (22) (31) 
339 140 208 150 
(138) (43) (35) (79) 
660 248 423 321 
(171) (76) (85) (95) 
949 362 637 494 
(173) (107) (116) (122) 
CAPE COBRA 
Dorsal Dorsal Ventral Ventral 
outside inside outside inside 
0 0 0 0 
1 2 6 7 
(0) (0) (3) (1) 
21 4 21 19 
(1) (1) (4) (1) 
41 10 40 33 
(1) (1) (7) (3) 
84 27 94 80 
(14) (3) (18) (11) 
190 54 177 134 
(59) (5) (43) (15) 
333 80 283 192 
(66) (9) (56) (16) 
136 
European Pharmacopoeia diffusion cell apparatus: 
Total amount liberated in f.lg/cm2 
( )=standard deviation 
n=5 
AFRICAN ROCK PYTHON 
Time Dorsal Dorsal Ventral 
outside inside outside 
0 0 0 0 
2 20 20 20 
(0) (0) (0) 
4 50 40 60 
(0) (0) (0) 
8 140 100 180 
(0) (0) (0) 
24 560 310 810 
(100) (0) (0) 
48 1160 580 1670 
(100) (0) (100) 
72 1660 840 2140 
(100) (100) (100) 
EGYPTIAN COBRA 
Time Dorsal Dorsal Ventral 
outside inside outside 
0 0 0 0 
2 20 20 20 
(0) (0) (0) 
4 20 30 20 
(0) (0) (0) 
8 40 50 60 
(0) (0) (0) 
24 130 150 270 
(0) (0) (100) 
48 340 310 600 
(0) (0) (100) 
72 560 470 930 
(0) (100) (100) 
Ventral 
inside 
0 
40 
(0) 
70 
(0) 
140 
(0) 
490 
(0) 
1070 
(100) 
1600 
(100) 
Ventral 
inside 
0 
30 
(0) 
30 
(0) 
60 
(0) 
200 
(0) 
400 
(0) 
590 
(0) 
FOREST COBRA 
Dorsal Dorsal Ventral Ventral 
outside inside outside inside 
0 0 0 0 
40 20 70 40 
(0) (0) (0) (0) 
70 30 80 60 
(0) (0) (0) (0) 
170 50 170 120 
(0) (0) (0) (0) 
570 160 550 330 
(0) (0) (0) (0) 
1130 310 1200 640 
(100) (0) (200) (100) 
1640 490 1600 1000 
(100) (0) (100) (100) 
CAPE COBRA 
Dorsal Dorsal Ventral Ventral 
outside inside outside inside 
0 0 0 0 
10 10 40 10 
(0) (0) (0) (0) 
10 20 130 20 
(0) (0) (0) (0) 
20 40 230 40 
(0) (0) (0) (0) 
110 70 370 130 
(0) (0) (0) (0) 
300 110 570 270 
(0) (0) (0) (0) 
420 150 820 400 
(0) (0) (100) (0) 
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